View Filing Data

Print Document View Excel Document

DOCUMENT AND ENTITY INFORMATION DOCUMENT AND ENTITY INFORMATION - USD ($)	12 Months Ended
	Mar. 30, 2013	Apr. 27, 2013	Sep. 29, 2012
Document And Entity Information [Abstract]
Entity Registrant Name	HAEMONETICS CORP
Entity Central Index Key	0000313143
Current Fiscal Year End Date	--03-30
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Mar. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		51,076,655
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 2,031,424,216

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Net revenues	$ 891,990	$ 727,844	$ 676,694
Cost of goods sold	463,859	358,604	321,485
Gross profit	428,131	369,240	355,209
Operating expenses:
Research and development	44,394	36,801	32,656
Selling, general and administrative	323,053	245,261	213,899
Contingent consideration income	0	(1,580)	(1,894)
Asset write-down	4,247	0	0
Total operating expenses	371,694	280,482	244,661
Operating income	56,437	88,758	110,548
Other income (expense), net	(6,540)	740	(467)
Income before provision for income taxes	49,897	89,498	110,081
Provision for income taxes	11,097	22,612	30,101
Net income	$ 38,800	$ 66,886	$ 79,980
Net income per share - basic (in dollars per share)	$ 0.76	$ 1.32	$ 1.59
Net income per share - diluted (in dollars per share)	$ 0.74	$ 1.30	$ 1.56
Weighted average shares outstanding
Basic (in shares)	51,349	50,727	50,154
Diluted (in shares)	52,259	51,590	51,192

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Net income	$ 38,800	$ 66,886	$ 79,980
Other comprehensive (loss)/income:
Impact of defined benefit plans, net of tax	(820)	(3,988)	555
Foreign currency translation adjustment	(4,705)	(2,813)	6,380
Unrealized (loss)/gain on cash flow hedges, net of tax	4,594	3,140	(4,068)
Reclassifications into earnings of cash flow hedge losses/(gains), net of tax	(2,746)	3,230	769
Other comprehensive (loss)/income	(3,677)	(431)	3,636
Comprehensive income	$ 35,123	$ 66,455	$ 83,616

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

- Definition

Net of tax amount of the income statement impact of the reclassification adjustment of accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges realized in net income. Also includes reclassification adjustments of an entity's share of an equity investee's deferred hedging gain (loss) realized in net income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e689-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 24
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 18, 19
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 31, 46
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

Net of tax amount, before reclassification adjustments, of the change in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges. Also includes an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17, 20
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 121
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 46
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 24
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 30, 2013	Mar. 31, 2012
Current assets:
Cash and cash equivalents	$ 179,120	$ 228,861
Accounts receivable, less allowance of $1,727 at March 30, 2013 and $1,480 at March 31, 2012	170,111	135,464
Inventories, net	183,784	117,163
Deferred tax asset, net	13,782	9,665
Prepaid expenses and other current assets	50,213	35,976
Total current assets	597,010	527,129
Property, plant and equipment:
Land, building and building improvements	82,898	59,816
Plant equipment and machinery	205,698	136,057
Office equipment and information technology	103,235	88,185
Haemonetics equipment	240,889	226,476
Total property, plant and equipment	632,720	510,534
Less: accumulated depreciation	(375,767)	(348,877)
Net property, plant and equipment	256,953	161,657
Other assets:
Intangible assets	264,388	96,549
Goodwill	330,474	115,058
Deferred tax asset, long term	1,751	23
Other long-term assets	11,341	10,719
Total other assets	607,954	222,349
Total assets	1,461,917	911,135
Current liabilities:
Notes payable and current maturities of long-term debt	23,150	894
Accounts payable	49,893	35,425
Accrued payroll and related costs	45,697	29,451
Accrued income taxes	4,053	8,075
Other liabilities	57,351	56,899
Total current liabilities	180,144	130,744
Long-term debt, net of current maturities	456,944	2,877
Long-term deferred tax liability	29,552	23,332
Other long-term liabilities	26,095	21,551
Commitments and contingencies (Note 12)
Stockholders’ equity:
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 51,031,563 shares at March 30, 2013 and 50,603,798 shares at March 31, 2012	510	506
Additional paid-in capital	365,040	322,232
Retained earnings	398,199	400,783
Accumulated other comprehensive income	5,433	9,110
Total stockholders’ equity	769,182	732,631
Total liabilities and stockholders’ equity	$ 1,461,917	$ 911,135

CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($) $ in Thousands	Mar. 30, 2013	Mar. 31, 2012
Accounts receivable, allowance	$ 1,727	$ 1,480
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	51,036,207	50,603,798
Common stock, outstanding (in shares)	51,036,207	50,603,798

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income/(Loss) [Member]
Balance, value at Apr. 03, 2010	$ 593,124	$ 508	$ 252,070	$ 334,641	$ 5,905
Balance, shares (in shares) at Apr. 03, 2010		50,882
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan	3,681	$ 2	3,679
Employee stock purchase plan (in shares)		156
Exercise of stock options and related tax benefit	44,905	$ 20	44,885
Exercise of stock options and related tax benefit (in shares)		2,024
Shares repurchased	(50,000)	$ (18)	(8,991)	(40,991)
Shares repurchased (in shares)		(1,814)
Issuance of restricted stock, net of cancellations	0	$ 1	(1)
Issuance of restricted stock, net of cancellations (in shares)		72
Stock compensation expense	10,810		10,810
Net income	79,980			79,980
Other comprehensive income/(loss)	3,636
Balance, value at Apr. 02, 2011	686,136	$ 513	302,452	373,630	9,541
Balance, shares (in shares) at Apr. 02, 2011		51,320
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan	3,723	$ 2	3,721
Employee stock purchase plan (in shares)		154
Exercise of stock options and related tax benefit	17,028	$ 7	17,021
Exercise of stock options and related tax benefit (in shares)		738
Shares repurchased	(49,998)	$ (17)	(10,248)	(39,733)
Shares repurchased (in shares)		(1,704)
Issuance of restricted stock, net of cancellations	1	$ 1
Issuance of restricted stock, net of cancellations (in shares)		96
Stock compensation expense	9,286		9,286
Net income	66,886			66,886
Other comprehensive income/(loss)	(431)
Balance, value at Mar. 31, 2012	732,631	$ 506	322,232	400,783	9,110
Balance, shares (in shares) at Mar. 31, 2012		50,604
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan	4,142	$ 1	4,141
Employee stock purchase plan (in shares)		151
Exercise of stock options and related tax benefit	35,815	$ 14	35,801
Exercise of stock options and related tax benefit (in shares)		1,398
Stock-based compensation adjustment related to acquisition	504		504
Shares repurchased	(50,003)	$ (12)	(8,607)	(41,384)
Shares repurchased (in shares)		(1,236)
Issuance of restricted stock, net of cancellations	1	$ 1
Issuance of restricted stock, net of cancellations (in shares)		115
Stock compensation expense	10,969		10,969
Net income	38,800
Other comprehensive income/(loss)	(3,677)
Balance, value at Mar. 30, 2013	$ 769,182	$ 510	$ 365,040	$ 398,199	$ 5,433
Balance, shares (in shares) at Mar. 30, 2013		51,032

CONSOLIDATED STATEMENTS OF CASH FLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Cash Flows from Operating Activities:
Net income	$ 38,800,000	$ 66,886,000	$ 79,980,000
Non cash items:
Depreciation and amortization	65,481,000	49,966,000	48,145,000
Amortization of financing costs	1,139,000	0	0
Stock compensation expense	10,969,000	9,286,000	10,810,000
Deferred tax expense	589,000	5,878,000	5,782,000
Loss on sale of property, plant and equipment	351,000	772,000	674,000
Unrealized loss from hedging activities	700,000	166,000	(614,000)
Contingent consideration income	0	(1,580,000)	(1,894,000)
Reversal of interest expense on contingent consideration	0	(574,000)	(416,000)
Asset write-off	4,247,000	0	0
Change in operating assets and liabilities:
Increase in accounts receivable, net	(38,080,000)	(10,539,000)	(3,920,000)
Increase in inventories	(18,685,000)	(32,528,000)	(2,560,000)
(Increase)/decrease in prepaid income taxes	(4,025,000)	3,058,000	1,680,000
(Increase)/decrease in other assets and other long-term liabilities	(6,187,000)	3,156,000	(470,000)
Tax benefit of exercise of stock options	4,194,000	1,958,000	4,941,000
(Decrease)/increase in accounts payable and accrued expenses	25,581,000	19,413,000	(18,683,000)
Net cash provided by operating activities	85,074,000	115,318,000	123,455,000
Cash Flows from Investing Activities:
Capital expenditures on property, plant and equipment	(62,188,000)	(53,198,000)	(46,669,000)
Proceeds from sale of property, plant and equipment	1,968,000	1,002,000	1,468,000
Acquisition of Whole Blood Business	(535,175,000)	0	0
Acquisition of Global Med Technologies	0	0	(128,000)
Acquisition of ACCS	0	0	(6,229,000)
Investment in Hemerus	(1,000,000)	0	0
Net cash used in investing activities	(596,395,000)	(52,196,000)	(51,558,000)
Cash Flows from Financing Activities:
Payments on long-term real estate mortgage	(886,000)	(815,000)	(632,000)
Net (decrease)/increase in short-term loans	7,446,000	(288,000)	(15,153,000)
Term loan borrowings	475,000,000	0	0
Debt issuance costs	(5,467,000)	0	0
Proceeds from employee stock purchase plan	4,142,000	3,723,000	3,681,000
Proceeds from exercise of stock options	27,517,000	15,475,000	40,896,000
Excess tax benefit on exercise of stock options	4,101,000	1,433,000	3,124,000
Share repurchase	(50,000,000)	(49,998,000)	(50,000,000)
Net cash provided by (used in) financing activities	461,853,000	(30,470,000)	(18,084,000)
Effect of exchange rates on cash and cash equivalents	(273,000)	(498,000)	1,332,000
Net (Decrease)/Increase in Cash and Cash Equivalents	(49,741,000)	32,154,000	55,145,000
Cash and Cash Equivalents at Beginning of Year	228,861,000	196,707,000	141,562,000
Cash and Cash Equivalents at End of Period	179,120,000	228,861,000	196,707,000
Non-cash Investing and Financing Activities:
Transfers from inventory to fixed assets for placement of Haemonetics equipment	21,677,000	18,333,000	5,069,000
Supplemental Disclosures of Cash Flow Information:
Interest paid	5,910,000	414,000	487,000
Income taxes paid	$ 13,178,000	$ 10,764,000	$ 16,669,000

DESCRIPTION OF BUSINESS	12 Months Ended
DESCRIPTION OF BUSINESS	Mar. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION	DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION Haemonetics is a global healthcare company dedicated to providing innovative blood management solutions for our customers — plasma collectors, blood collectors, and hospitals. Anchored by our strong brand name in medical device systems for the transfusion industry, we also provide information technology platforms and value added services to provide customers with business solutions which support improved clinical outcomes for patients and efficiency in the blood supply chain. Our systems automate the collection and processing of donated blood; perform blood diagnostics; salvage and process surgical patient blood; and dispense blood within the hospital. These systems include devices and single-use, proprietary disposable sets that operate only on our specialized equipment. Our manual blood collection and filtration systems enable the manual collection of all blood components while detecting bacteria, thus reducing the risks of infection through transfusion. Our blood processing systems allow users to collect and process only the blood component(s) they target — plasma, platelets, or red blood cells — increasing donor and patient safety as well as collection efficiencies. Our blood diagnostics system assesses the likelihood of a patient’s blood loss allowing clinicians to make informed decisions about a patient’s treatment as it relates to blood loss in surgery. Our surgical blood salvage systems collect blood lost by a patient in surgery, clean the blood, and make it available for reinfusion to the patient, in this way giving the patient the safest blood possible — his or her own. Our blood distribution systems are “smart” refrigerators located throughout hospitals which automate the storage, inventory tracking, and dispositioning of blood in key blood use areas. Our information technology platforms are used by blood and plasma collectors to improve the safety and efficiency of blood collection logistics by eliminating previously manual functions at not-for-profit blood centers and commercial plasma centers. Our platforms are also used by hospitals to enable hospital administrators to monitor and measure blood management practices and to manage processes within transfusion services. Our information technology platforms allow all customers to better manage processes across the blood supply chain, comply with regulatory requirements, and identify increased opportunities to reduce costs. On November 30, 2012 the Company completed a two-for-one split of the Company's common stock in the form of a stock dividend. Unless otherwise indicated, all common stock shares and per share information referenced within the Consolidated Financial Statements have been retroactively adjusted to reflect the stock split. The exercise price of each outstanding option has also been proportionately and retroactively adjusted for all periods presented. Par value per share and authorized shares were however not affected by the stock split. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The accompanying consolidated financial statements present separately our financial position, results of operations, cash flows, and changes in shareholders’ equity. All amounts presented, except per share amounts, are stated in thousands of U.S. dollars, unless otherwise indicated. The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated, and these financial statements reflect those material items that arose after the balance sheet date but prior to the issuance of the financial statements that would be considered recognized subsequent events. Refer to Note 19 - Subsequent Events for further information.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 94-6
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 2-6
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 4, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4/FIN46(R)-8
-Paragraph 8, C1, C7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS

12 Months Ended

Mar. 30, 2013

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Fiscal Year

Our fiscal year ends on the Saturday closest to the last day of March. Fiscal years 2013, 2012 and 2011each includes 52 weeks with each quarter having 13 weeks.

Principles of Consolidation

The accompanying consolidated financial statements include all accounts including those of our subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could vary from the amounts derived from our estimates and assumptions.

Revenue Recognition

Our revenue recognition policy is to recognize revenues from product sales, software and services in accordance with ASC Topic 605, Revenue Recognition, and ASC Topic 985-605, Software. These standards require that revenues are recognized when persuasive evidence of an arrangement exists, product delivery, including customer acceptance, has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. When more than one element such as equipment, disposables, and services are contained in a single arrangement, we allocate revenue between the elements based on each element’s relative selling price, provided that each element meets the criteria for treatment as a separate unit of accounting. An item is considered a separate unit of accounting if it has value to the customer on a stand-alone basis. The selling price of the undelivered elements is determined by the price charged when the element is sold separately, or in cases when the item is not sold separately, by third-party evidence of selling price or by management's best estimate of selling price. For our software arrangements accounted for under the provisions of ASC 985-605, Software, we establish fair value of undelivered elements based upon vendor specific objective evidence.

Product Revenues

Product sales consist of the sale of our disposable whole blood and blood component collection sets, equipment devices and the related disposables used with these devices. On product sales to end customers, revenue is recognized when both the title and risk of loss have transferred to the customer as determined by the shipping terms and all obligations have been completed. For product sales to distributors, we recognize revenue for both equipment and disposables upon shipment of these products to our distributors. Our standard contracts with our distributors state that title to the equipment passes to the distributors at point of shipment to a distributor’s location. The distributors are responsible for shipment to the end customer along with installation, training and acceptance of the equipment by the end customer. Shipments to distributors are not contingent upon resale of the product.

Non-Income Taxes

We are required to collect sales or valued added taxes in connection with the sale of certain of our products. We report revenues net of these amounts as they are promptly remitted to the relevant taxing authority.

We are also required to pay a medical device excise tax relating to U.S. sales of Class I, II and III medical devices. This new excise tax went into effect January 1, 2013, established as part of the March 2010 U.S. healthcare reform legislation, and has been included in selling, general and administrative expenses.

Software Revenues

Our software solutions business provides support to our plasma and blood collection customers and hospitals. We provide information technology platforms and technical support for donor recruitment, blood and plasma testing laboratories, and for efficient and compliant operations of blood and plasma collection centers. For plasma customers, we also provide information technology platforms for managing distribution of plasma from collection centers to plasma fractionation facilities.

Our software solutions revenues also include revenue from software sales which includes per collection or monthly subscription fees for the license and support of the software as well as hosting services. A significant portion of our software sales are perpetual licenses typically accompanied with significant implementation service fees related to software customization as well as other professional and technical service fees.

We generally recognize revenue from the sale of perpetual licenses on a percentage-of-completion basis which requires us to make reasonable estimates of the extent of progress toward completion of the contract. These arrangements most often include providing customized implementation services to our customer. We also provide other services, including in some instances hosting, technical support, and maintenance, for the payment of periodic, monthly, or quarterly fees. We recognize these fees and charges as earned, typically as these services are provided during the contract period.

Translation of Foreign Currencies

All assets and liabilities of foreign subsidiaries are translated at the rate of exchange at year-end while sales and expenses are translated at an average rate in effect during the year. The net effect of these translation adjustments is shown in the accompanying financial statements as a component of stockholders' equity. Foreign currency transaction gains and losses, including those resulting from inter-company transactions, are included in other income, net on the consolidated statements of income. The impact of foreign exchange on long-term intercompany loans are recorded in accumulated other comprehensive income on the consolidated balance sheet.

Cash and Cash Equivalents

Cash equivalents include various instruments such as money market funds, U.S. government obligations and commercial paper with maturities of three months or less at date of acquisition. Cash and cash equivalents are recorded at cost, which approximates fair market value. As of March 30, 2013, our cash and cash equivalents consisted of investments in United States Government Agency and Institutional Money Market Funds.

Allowance for Doubtful Accounts

We establish a specific allowance for customers when it is probable that they will not be able to meet their financial obligation. Customer accounts are reviewed individually on a regular basis and appropriate reserves are established as deemed appropriate. We also maintain a general reserve using a percentage that is established based upon the age of our receivables. We establish allowances for balances not yet due and past due accounts based on past experience.

Property, Plant and Equipment

Property, plant and equipment is recorded at historical cost. We provide for depreciation and amortization by charges to operations using the straight-line method in amounts estimated to recover the cost of the building and improvements, equipment, and furniture and fixtures over their estimated useful lives as follows:



Asset Classification		Estimated Useful Lives
Building		30 years
Building improvements		5-20 Years
Plant equipment and machinery		3-10 Years
Office equipment and information technology		3-10 Years
Haemonetics equipment		3-7 Years

We evaluate the depreciation periods of property, plant and equipment to determine whether events or circumstances warrant revised estimates of useful lives. All property, plant and equipment are also tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.

Our installed base of devices includes devices owned by us and devices sold to the customer. The asset on our balance sheet entitled Haemonetics equipment consists of medical devices installed at customer sites but owned by Haemonetics. Generally the customer has the right to use it for a period of time as long as they meet the conditions we have established, which among other things, generally include one or more of the following:


•	Purchase and consumption of a certain level of disposable product


•	Payment of monthly rental fees


•	An asset utilization performance metric, such as performing a minimum level of procedures per month per device

Consistent with the impairment tests noted below for other intangible assets subject to amortization, we review Haemonetics equipment and their related useful lives at least once a year, or more frequently if certain conditions arise, to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. To conduct these reviews we estimate the future amount and timing of demand for these devices. Changes in expected demand can result in additional depreciation expense, which is classified as cost of goods sold. Any significant unanticipated changes in demand could impact the value of our devices and our reported operating results.

Leasehold improvements are amortized over the lesser of their useful lives or the term of the lease. Maintenance and repairs are expensed to operations as incurred. When equipment and improvements are sold or otherwise disposed of, the asset cost and accumulated depreciation are removed from the accounts, and the resulting gain or loss, if any, is included in the statements of income.

Goodwill and Intangible Assets

Intangible assets acquired in a business combination are recorded under the purchase method of accounting at their estimated fair values at the date of acquisition. Goodwill represents the excess purchase price over the fair value of the net tangible and other identifiable intangible assets acquired. We amortize our other intangible assets over their estimated useful lives.

Goodwill is not amortized. Instead goodwill is reviewed for impairment at least annually in accordance with ASC Topic 350, Intangibles — Goodwill and Other. We perform our annual impairment test on the first day of the fiscal fourth quarter for each of our reporting units. We first perform a qualitative test and if necessary, perform a quantitative test. The quantitative test is based on a discounted cash flow analysis for each reporting unit. Discounted cash flow analysis is an income approach to determining fair value of a reporting unit utilizing estimated after-tax cash flows attributable to the reporting unit which are then discounted to present value based on a risk-adjusted discount rate. The amount and timing of future cash flows for this analysis are determined primarily based on revenue growth rates, operating margins and other projections from our most recent operational budgets and long range strategic plans. The test showed no evidence of impairment to our goodwill for fiscal 2013, 2012 or 2011 and demonstrated that the fair value of each reporting unit significantly exceeded the reporting unit’s carrying value in each period.

We review intangible assets subject to amortization at least annually or more frequently if certain conditions arise to determine if any adverse conditions exist that would indicate that the carrying value of an asset or asset group may not be recoverable, or that a change in the remaining useful life is required. Conditions indicating that an impairment exists include but are not limited to a change in the competitive landscape, internal decisions to pursue new or different technology strategies, a loss of a significant customer or a significant change in the marketplace including prices paid for our products or the size of the market for our products.

If an impairment indicator exists, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset (asset group) exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset (asset group), we will write the carrying value down to the fair value in the period identified.

We generally calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset using a risk-adjusted discount rate. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset (asset group).

If we determine the estimate of an intangible asset's remaining useful life should be reduced based on our expected use of the asset, the remaining carrying amount of the asset is amortized prospectively over the revised estimated useful life.

Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed

ASC Topic 985-20, Software, specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers, at which point capitalized costs are amortized over their estimated useful life. Technological feasibility is established when we have a detailed design of the software and when research and development activities on the underlying device, if applicable, are completed.

We review the net realizable value of capitalized assets periodically to assess the recoverability of amounts capitalized. In the future, the net realizable value may be adversely affected by the loss of a significant customer or a significant change in the market place, which could result in an impairment being recorded.

Other Liabilities

Other liabilities represent items payable within the next twelve months.

The items included in the fiscal year end balances were:



(In thousands)	March 30, 2013		March 31, 2012
VAT Liabilities	$	5,121	$	6,875
Forward Contracts	1,786		1,185
Deferred Revenue	23,737		24,132
HS Core Liability (a)	156		3,654
All Other	26,551		21,053
Total	$	57,351	$	56,899


(a)	See Note 10, Commitments and Contingencies, for details of the HS Core quality issue that occurred during the first quarter of 2012.

Research and Development Expenses

All research and development costs are expensed as incurred.

Advertising Costs

All advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statement of income. Advertising expenses were $4.6 million, $4.5 million, and $2.8 million for 2013, 2012 and 2011, respectively.

Accounting for Shipping and Handling Costs

Shipping and handling costs are included in selling, general and administrative expenses. Freight is classified in cost of goods sold when the customer is charged for freight and in selling, general and administration when the customer is not explicitly charged for freight.

Income Taxes

The income tax provision is calculated for all jurisdictions in which we operate. This process involves estimating actual current taxes due plus assessing temporary differences arising from differing treatment for tax and accounting purposes that are recorded as deferred tax assets and liabilities. Deferred tax assets are periodically evaluated to determine their recoverability and a valuation allowance is established with a corresponding additional income tax provision recorded in our consolidated statements of income if their recovery is not considered more likely than not. The provision for income taxes could also be materially impacted if actual taxes due differ from our earlier estimates.

We record a liability for uncertain tax positions taken or expected to be taken in income tax returns. Uncertain tax positions are unrecognized tax benefits for which reserves have been established. Our financial statements reflect expected future tax consequences of such positions presuming the taxing authorities’ full knowledge of the position and all relevant facts.

We file income tax returns in all jurisdictions in which we operate. We establish reserves to provide for additional income taxes that may be due in future years as these previously filed tax returns are audited. These reserves have been established based on management’s assessment as to the potential exposure attributable to permanent differences and interest applicable to both permanent and temporary differences. All tax reserves are analyzed periodically and adjustments are made as events occur that warrant modification.

Derivative Instruments

We account for our derivative financial instruments in accordance with ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”) and with ASC Topic 815,Derivatives and Hedging (“ASC 815”). In accordance with ASC 815, we record all derivatives on the balance sheet at fair value. The accounting for the change in the fair value of derivatives depends on the intended use of the derivative, whether we have elected to designate a derivative as a hedging instrument for accounting purposes, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. In addition, ASC 815 provides that, for derivative instruments that qualify for hedge accounting, changes in the fair value are either (a) offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings or (b) recognized in equity until the hedged item is recognized in earnings, depending on whether the derivative is being used to hedge changes in fair value or cash flows. The ineffective portion of a derivative’s change in fair value is immediately recognized in earnings. We do not use derivative financial instruments for trading or speculation purposes.

The gains or losses on the forward foreign exchange rate contracts designated as hedges are recorded in net revenues, cost of goods sold, operating expenses and other income in our consolidated statements of income when the underlying hedged transaction affects earnings. The cash flows related to the gains and losses are classified in the consolidated statements of cash flows as part of cash flows from operating activities. For those derivative instruments that are not designated as part of a hedging relationship we record the gains or losses in earnings currently. These gains and losses are intended to offset the gains and losses recorded on net monetary assets or liabilities that are denominated in foreign currencies. We recorded foreign currency losses on designated and non-designated hedges of $0.8 million, $0.4 million, and $1.4 million in fiscal 2013, 2012 and 2011, respectively.

On a quarterly basis, we assess whether the cash flow hedges are highly effective in offsetting changes in the cash flow of the hedged item. We manage the credit risk of the counterparties by dealing only with institutions that we consider financially sound and consider the risk of non-performance to be remote.

Our derivative instruments do not subject our earnings or cash flows to material risk, as gains and losses on these derivatives are intended to offset losses and gains on the item being hedged. We do not enter into derivative transactions for speculative purposes and we do not have any non-derivative instruments that are designated as hedging instruments pursuant to ASC Topic 815.

Stock-Based Compensation

We use the Black-Scholes option-pricing model to calculate the grant-date fair value of our stock options. The following assumptions, which involve the use of judgment by management, are used in the computation of the grant-date fair value of our stock options:

Expected Volatility — We have principally used our historical volatility as a basis to estimate expected volatility in our valuation of stock options.

Expected Term — We estimate the expected term of our options using historical exercise and forfeiture data to determine the amount of stock based compensation to record each period. We believe that this historical data is currently the best estimate of the expected term of our new option grants.

Estimated Forfeiture Rate — Based on an analysis of our historical forfeitures, we have applied an annual forfeiture rate which represents the portion that we expect will be forfeited each year over the vesting period. We reevaluate this analysis periodically and adjust the forfeiture rate as necessary. Ultimately, we will only recognize expense for those shares that vest.

Valuation of Acquisitions

We allocate the amounts we pay for each acquisition to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition, including acquired identifiable intangible assets. We base the estimated fair value of identifiable intangible assets on detailed valuations that use historical information and market assumptions based upon the assumptions of a market participant. We allocate any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill. The use of alternative valuation assumptions, including estimated cash flows and discount rates, and alternative estimated useful life assumptions could result in different purchase price allocations and intangible asset amortization expense in current and future periods.

In certain acquisitions, we have earn-out arrangements or contingent consideration to provide potential future payments to the seller for achieving certain agreed-upon financial targets. We record the contingent consideration at its fair value at the acquisition date. Generally, we have entered into arrangements with contingent consideration that require payments in cash. As such, each quarter, we revalue the contingent consideration obligations associated with certain acquisitions to their then fair value and record the change in the fair value as contingent consideration income or expense. Increases or decreases in the fair value of the contingent consideration obligations can result from changes in assumed discount periods and rates, changes in the assumed timing and amount of revenue and expense estimates, and changes in assumed probability adjustments with respect to regulatory approval. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, future business and economic conditions, as well as changes in any of the assumptions described above, can materially impact the amount of contingent consideration income or expense we record in any given period.

Concentration of Credit Risk and Significant Customers

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable. Sales to one unaffiliated Japanese customer, the Japanese Red Cross Society, amounted to $90.1 million, $99.5 million, and $95.9 million for 2013, 2012, and 2011, respectively. Accounts receivable balances attributable to this customer accounted for 9.0%, 15.3%, and 13.7% of our consolidated accounts receivable at fiscal year ended 2013, 2012, and 2011. While the accounts receivable related to the Japanese Red Cross Society may be significant, we do not believe the credit loss risk to be significant given the consistent payment history by this customer.

Certain other markets and industries can expose us to concentrations of credit risk. For example, in our commercial plasma business, our sales are concentrated with several large customers. As a result, our accounts receivable extended to any one of these commercial plasma customers can be somewhat significant at any point in time. Also, a portion of our trade accounts receivable outside the United States include sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the financial stability and creditworthiness of those countries’ national economies. We have not incurred significant losses on government receivables. We continually evaluate all government receivables for potential collection risks associated with the availability of government funding and reimbursement practices. If the financial condition of customers or the countries’ healthcare systems deteriorate such that their ability to make payments is uncertain, allowances may be required in future periods.

Deteriorating credit and economic conditions in parts of Western Europe, particularly in Italy, where our net accounts receivable was $23.4 million and $21.0 million for the fiscal years ended March 30, 2013 and March 31, 2012, may increase the average length of time it takes us to collect accounts receivable in certain regions within these countries.

Recent Accounting Pronouncements

In February 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. This Update requires an entity to disclose the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under U.S. GAAP to be reclassified in its entirety to net income. The objective of this disclosure is to improve the reporting of reclassifications out of accumulated other comprehensive income. The amended guidance is effective for annual reporting periods beginning after December 15, 2012, and interim periods within those annual periods. We are currently evaluating the impact, if any, that the adoption of this pronouncement may have on our financial disclosures.

In October 2012, the FASB issued ASU 2012-04, Technical Corrections and Improvements. The amendments in this update cover a wide range of Topics in the Accounting Standards Codification. These amendments include technical corrections and improvements to the Accounting Standards Codification and conforming amendments related to fair value measurements. The amendments in this update will be effective for fiscal periods beginning after December 15, 2012. The adoption of ASU 2012-04 is not expected to have a material impact on our financial position or results of operations.

In December 2011, the FASB issued ASU No. 2011-11 Balance Sheet: Disclosures about Offsetting Assets and Liabilities. This Update requires an entity to disclose information about offsetting and related arrangements to enable users of its financial statements to understand the effect of those arrangements on its financial position. The objective of this disclosure is to facilitate comparison between those entities that prepare their financial statements on the basis of U.S. GAAP and those entities that prepare their financial statements on the basis of IFRS. The amended guidance is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. We are currently evaluating the impact, if any, that the adoption of this pronouncement may have on our financial disclosures.

Standards Implemented

In June 2011, the FASB issued ASU No. 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income. Update No. 2011-05 updates the disclosure requirements for comprehensive income to include total comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. The updated guidance does not affect how earnings per share is calculated or presented. The updated guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011, and should be applied retrospectively. We adopted this standard in the first quarter of fiscal 2013 using the two separate but consecutive statements approach. The adoption of ASU 2011-05 does not have an effect on our financial position or results of operations but changed our presentation of comprehensive income.

In September 2011, the FASB issued ASU No. 2011-08,Testing Goodwill for Impairment ("ASU 2011-08"), which changes the way a company completes its annual impairment review process. The provisions of this pronouncement provides an entity with the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that is more likely than not that the fair value of a reporting unit is less than its carrying amount. ASU-2011-08 allows an entity the option to bypass the qualitative-assessment for any reporting unit in any period and proceed directly to performing the first step of the two-step goodwill impairment test. The pronouncement does not change the current guidance for testing other indefinite-lived intangible assets for impairment. This standard is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011. We adopted these provisions in 2012. The adoption of ASU 2011-08 did not have a material effect on our financial position or results of operations.

ACQUISITIONS

12 Months Ended

Mar. 30, 2013

Business Combinations [Abstract]

ACQUISITIONS

Acquisitions were completed in fiscal 2013 and fiscal 2011 as part of our growth initiatives. We did not complete any acquisitions during fiscal 2012.

Fiscal Year 2013 Acquisition

Whole Blood Acquisition

On August 1, 2012, we completed the acquisition from Pall Corporation (“Pall”) of substantially all of the assets relating to its blood collection, filtration, processing, storage, and re-infusion product lines, and all of the outstanding equity interest in Pall Mexico Manufacturing, S. de R.L. de C.V., a subsidiary of Pall based in Mexico pursuant to an Asset Purchase Agreement (the “Purchase Agreement”) with Pall. We refer to the acquired business as the “whole blood business.”

At the closing of the transaction, we paid a total consideration of $535.2 million in cash and $0.5 million in shares following resolution of post-closing adjustments for working capital and historical earnings levels. We anticipate paying an additional $15.0 million upon replication and delivery of certain manufacturing assets of Pall's filter media business to Haemonetics by 2016. Until that time, Pall will manufacture and sell filter media to Haemonetics under a supply agreement.

We entered into a credit agreement on August 1, 2012 in connection with the transaction which includes a $475.0 million term loan to fund the majority of the cash paid to Pall. See Note 8 for a detailed description of the key terms and provisions of the credit agreement.

We acquired the whole blood business to provide access to the manual collection and whole blood markets and provide scope for introduction of automated solutions in those markets. The whole blood business manufactures and sells manual blood collection systems and filters and has operations in North America, Europe and Asia Pacific countries. Revenue from the sale of whole blood disposables has been reported within the blood center disposables product line since the date of acquisition.

The assets and liabilities acquired from Pall were recorded at fair value at the date of acquisition. During the current period, we updated the fair value of assets and liabilities recorded as of the date of acquisition with a corresponding adjustment to goodwill to reflect such updates to the allocation of purchase price. There were no significant changes to the consolidated statement of income during fiscal 2013 as a result of the changes to fair value.

The allocation of purchase price is preliminary, and subject to change based primarily on finalization of the assessment of the value of deferred taxes and assumed liabilities. We expect to complete these valuations by June 30, 2013.

The preliminary allocation of the purchase price to the estimated fair value of the acquired assets and liabilities is summarized as follows:



Asset class	Amounts Recognized as of March 30, 2013 (Provisional)
(In thousands)
Inventories	$	49,917
Property, plant and equipment	85,984
Intangible assets	188,500
Other assets/liabilities, net	(6,166		)
Goodwill	216,940
Fair value of net assets acquired	$	535,175

The adjusted fair value of the acquired assets and liabilities are reflected in the Consolidated Balance Sheets.

The provisional allocation of purchase price changed as compared to the initial allocation as of September 29, 2012 as follows: inventory was reduced by $2.5 million, property, plant and equipment increased $15.3 million, intangible assets decreased $18.3 million, assumed liabilities increased $4.4 million and goodwill increased by $9.9 million.

The $188.5 million of acquired intangible assets was allocated to acquired technology and customer relationships at fair values of $61.0 million and $127.5 million, respectively. The acquired assets are amortized over the estimate of their useful lives of 12 years on a straight-line basis. We adopted the straight-line amortization and shortened the useful lives to 12 years as it best reflects the pattern of benefits. We recorded $10.5 million in amortization expense relating to the acquired intangible assets for the fiscal year ended March 30, 2013.

Goodwill represents the excess of the purchase price over the fair value of the net assets. Goodwill of $216.9 million represents future economic benefits expected to arise from work force at the various plants and locations and significant technological know-how in filter manufacturing. All of the domestic goodwill is deductible for tax purposes.

Revenue for the whole blood business from acquisition was $138.4 million.

We recognized $3.2 million and $3.0 million of transaction costs related to the whole blood acquisition in the selling, general and administrative line item in the accompanying consolidated statements of income for the fiscal years ended March 30, 2013 and March 31, 2012, respectively.

The following represents the pro forma consolidated statements of income as if the acquisition of the whole blood business had been included in our consolidated results beginning on April 3, 2011.



(In thousands)	March 30, 2013		March 31, 2012
Net sales	$	963,923	$	963,643
Net income	56,540		77,984
Basic earnings per share	$	1.10	$	1.54
Diluted earnings per share	$	1.08	$	1.51

The unaudited consolidated pro-forma financial information above includes the following significant adjustments made to account for certain costs which would have been incurred if the acquisition had been completed on April 3, 2011, as adjusted for the applicable tax impact. As our acquisition of the whole blood business was completed on August 1, 2012, the pro-forma adjustments for the fiscal year ended March 30, 2013 in the table below only include the required adjustments through August 1, 2012.



(In thousands)	March 30, 2013			March 31, 2012
Transaction costs (1)	$	3,184		$	3,000
Amortization of inventory fair value adjustment (2)	11,948			(11,948		)
Amortization of acquired intangible assets (3)	(5,236		)	(15,708		)
Interest expense incurred on acquisition financing (4)	(3,173		)	(9,520		)
Selling, general and administrative expenses (5)	(3,513		)	(10,540		)


(1)	Eliminated transactions costs as these non-recurring costs were incurred in fiscal 2013.

(2)

Added additional expense in the period ended March 31, 2012 to reflect the inventory fair value adjustments which would have been amortized had the transaction been consummated on April 3, 2011 as the corresponding inventory would have been completely sold during the first two quarters of 2011. Also, deducted the actual inventory fair value adjustment recorded in the fiscal year ended March 30, 2013 to reflect the pro-forma consumption of inventory in 2011.


(3)	Added additional amortization of the acquired whole blood intangible assets recognized at fair value in purchase accounting.


(4)	Added additional interest expense for the debt used to finance the acquisition.

(5)

Additional investments in infrastructure costs to replicate certain support functions performed by division or corporate organizations of Pall that did not transfer in the acquisition. These costs are primarily related to information technology infrastructure and application costs, and personnel costs required to expand regional and corporate administrative and sales support functions. These costs are not intended to be representative of actual costs incurred by Pall Corporation, and represent Haemonetics' best estimate of future incremental costs on an annualized basis. Actual incremental investments may differ from these estimates.

Prior to the acquisition, we had purchased filters from the whole blood business for inclusion in some of our devices. The transactional value between both parties approximated $10.0 million which was recorded by Pall as revenue and by us as a cost of sale. At the acquisition date, we owed Pall $1.4 million which has been settled as of March 30, 2013.

Fiscal Year 2011 Acquisition

ACCS Acquisition

On December 28, 2010, Haemonetics acquired certain assets of Applied Critical Care Services, Inc. (ACCS) for $6.4 million. ACCS was a manufacturer’s representative for Haemonetics engaged in the selling and servicing of the TEG analyzer product line. The purchase price was allocated to customer relationships of $4.5 million, other liabilities of $0.8 million, and goodwill of $2.7 million. Pro forma information is not provided as it is immaterial.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1383-128463

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 88-16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph F4
-Subparagraph e
-Appendix F

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51, 52
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 67-73
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

PRODUCT WARRANTIES

12 Months Ended

Mar. 30, 2013

Product Warranties [Abstract]

PRODUCT WARRANTIES

We generally provide a warranty on parts and labor for one year after the sale and installation of each device. We also warrant our disposables products through their use or expiration. We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary.



(In thousands)	March 30, 2013			March 31, 2012
Warranty accrual as of the beginning of the period	$	796		$	1,273
Warranty provision	1,180			2,430
Warranty spending	(1,303		)	(2,907		)
Warranty accrual as of the end of the period	$	673		$	796

INVENTORIES

12 Months Ended

Mar. 30, 2013

Inventory Disclosure [Abstract]

INVENTORIES

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined on the first-in, first-out method.



(In thousands)	March 30, 2013		March 31, 2012
Raw materials	$	70,716	$	41,219
Work-in-process	7,829		4,640
Finished goods	105,239		71,304
	$	183,784	$	117,163

GOODWILL AND INTANGIBLE ASSETS

12 Months Ended

Mar. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS

The changes in the carrying amount of goodwill for fiscal 2013 and 2012 are as follows:



(In thousands)
Carrying amount as of April 2, 2011	$	115,367
Effect of change in foreign currency exchange rates	(309		)
Carrying amount as of March 31, 2012	$	115,058
Whole blood business (a)	216,940
Effect of change in foreign currency exchange rates	(1,524		)
Carrying amount as of March 30, 2013	$	330,474


(a)	See Note 3, Acquisitions, for a full description of the acquisition of the whole blood assets, which occurred on August 1, 2012.

Intangible Assets

Intangible assets include the value assigned to license rights and other developed technology, patents, customer contracts and relationships and a trade name. The estimated useful lives for all of these intangible assets are 2 to 19 years.

Aggregate amortization expense for amortized intangible assets for fiscal year 2013, 2012, and 2011 was $22.1 million, $11.4 million, and $11.1 million, respectively. Future annual amortization expense on intangible assets is expected to approximate $26.2 million for fiscal year 2014, $24.9 million for fiscal year 2015, $24.6 million for fiscal year 2016, $24.5 million for fiscal year 2017 and $23.7 million for fiscal year 2018.



	Gross Carrying Amount		Accumulated Amortization		Net		Weighted Average Useful Life
	(In thousands)		(In thousands)		(In thousands)		(In years)
As of March 30, 2013
Patents	$	8,706	$	6,397	$	2,309	10
Capitalized software	26,841		2,333		24,508		6
Other developed technology	99,486		24,843		74,643		12
Customer contracts and related relationships	196,365		36,552		159,813		12
Trade names	5,383		2,268		3,115		10
Total intangibles	$	336,781	$	72,393	$	264,388	11



	Gross Carrying Amount		Accumulated Amortization		Net		Weighted Average Useful Life
	(In thousands)		(In thousands)		(In thousands)		(In years)
As of March 31, 2012
Patents	$	13,463	$	7,843	$	5,620	11
Capitalized software	20,597		1,394		19,203		6
Other developed technology	42,693		20,120		22,573		11
Customer contracts and related relationships	69,361		23,639		45,722		12
Trade names	5,408		1,977		3,431		10
Total intangibles	$	151,522	$	54,973	$	96,549	11

The changes to the net carrying value of our intangible assets from March 31, 2012 to March 30, 2013 reflect acquisition of the whole blood intangible assets, amortization expense and the effect of exchange rate changes in the translation of our intangible assets held by our international subsidiaries. Also contributing to the change was an asset write-off recorded in the fourth quarter of fiscal 2013 associated with exiting activities related to technologies originally acquired from Arryx, Inc. The total asset write-off related to abandoning Arryx-related assets was $4.2 million, net of $0.9 million of proceeds from the sale of certain intellectual property.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

DERIVATIVES AND FAIR VALUE MEASUREMENTS

12 Months Ended

Mar. 30, 2013

Derivatives and Fair Value Measurements [Abstract]

DERIVATIVES AND FAIR VALUE MEASUREMENTS

We manufacture, market and sell our products globally. For the fiscal year ended March 30, 2013, approximately 49.0% of our sales were generated outside the U.S. in local currencies. We also incur certain manufacturing, marketing and selling costs in international markets in local currency.

Accordingly, our earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, our reporting currency. We have a program in place that is designed to mitigate our exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize for a period of time, the unforeseen impact on our financial results from changes in foreign exchange rates. We utilize foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily the Japanese Yen and the Euro, and to a lesser extent the Swiss Franc, British Pound Sterling, Canadian Dollar and the Mexican Peso. This does not eliminate the volatility of foreign exchange rates, but because we generally enter into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation.

Designated Foreign Currency Hedge Contracts

All of our designated foreign currency hedge contracts as of March 30, 2013 and March 31, 2012 were cash flow hedges under ASC Topic 815, Derivatives and Hedging. We record the effective portion of any change in the fair value of designated foreign currency hedge contracts in Other Comprehensive Income in the Statement of Stockholders’ Equity until the related third-party transaction occurs. Once the related third-party transaction occurs, we reclassify the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, we would reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. We had designated foreign currency hedge contracts outstanding in the contract amount of $133.3 million as of March 30, 2013 and $162.1 million as of March 31, 2012.

During fiscal 2013, we recognized net gains of $2.5 million in earnings on our cash flow hedges, compared to recognized net losses of $3.2 million and $0.8 million during fiscal 2012 and 2011, respectively. For the fiscal year ended March 30, 2013, $5.1 million of gains, net of tax, were recorded in Other Comprehensive Income to recognize the effective portion of the fair value of any designated foreign currency hedge contracts that are, or previously were, designated as foreign currency cash flow hedges, as compared to net gains of $3.1 million, net of tax, for the fiscal year ended March 31, 2012 and net losses of $4.1 million, net of tax, for the fiscal year ended April 2, 2011. At March 30, 2013, gains of $5.1 million, net of tax, may be reclassified to earnings within the next twelve months. All currency cash flow hedges outstanding as of March 30, 2013 mature within twelve months.

Non-designated Foreign Currency Contracts

We manage our exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. We use foreign currency forward contracts as a part of our strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC Topic 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. We had non-designated foreign currency hedge contracts under ASC Topic 815 outstanding in the contract amount of $65.6 million as of March 30, 2013 and $45.5 million as of March 31, 2012.

Interest Rate Swaps

On August 1, 2012, we entered into a Credit Agreement which provided for a $475.0 million term loan (“Term Loan”). Under the terms of this Credit Agreement, the Company may borrow at a spread to an index, including the LIBOR index of 1-month, 3-months, 6-months, etc. From the date of the Credit Agreement, the Company has chosen to borrow against the 1-month USD-LIBOR-BBA rounded up, if necessary, to the nearest 1/16^th of 1% (“Adjusted LIBOR”). The terms of the Credit Agreement also allow us to borrow in multiple tranches. While we currently borrow in a single tranche, in the future, we may choose to borrow in multiple tranches.

Accordingly, our earnings and cash flows are exposed to interest rate risk from changes in Adjusted LIBOR. Part of our interest rate risk management strategy includes the use of interest rate swaps to mitigate our exposure to changes in variable interest rates. Our objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations.

On December 21, 2012, we entered into two interest rate swap agreements ("the swaps"), whereby we receive Adjusted LIBOR and pay an average fixed rate of 0.68% on a total notional value of $250.0 million of debt. The interest rate swaps mature on August 1, 2017. The Company designated the interest rate swaps as a cash flow hedge of variable interest rate risk associated with $250.0 million of indebtedness. For the fiscal year ended March 30, 2013, $0.8 million of losses, net of tax, were recorded in Accumulated Other Comprehensive Income to recognize the effective portion of the fair value of interest rate swaps that qualify as cash flow hedges. At March 30, 2013, losses of $0.1 million may be reclassified to earnings within the next twelve months.

Fair Value of Derivative Instruments

The following table presents the effect of our derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC Topic 815 in our consolidated statements of income for the fiscal year ended March 30, 2013.



Derivative Instruments	Amount of Gain/(Loss) Recognized in OCI (Effective Portion)			Amount of Gain/(Loss) Reclassified from OCI into Earnings (Effective Portion)			Location in Statement of Operations	Amount of Gain/(Loss) Excluded from Effectiveness Testing (*)			Location in Statement of Operations
(In thousands)
Designated foreign currency hedge contracts, net of tax	$	5,104		$	2,746		Net revenues, COGS, and SG&A	$	(337	)	Other income (expense), net
Non-designated foreign currency hedge contracts	—			—				$	1,214		Other income (expense)
Designated interest rate swaps, net of tax	$	(779	)	$	(269	)	Interest income (expense), net	$	—



(*)		We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.

We did not have fair value hedges or net investment hedges outstanding as of March 30, 2013 or March 31, 2012. Amounts recognized as deferred tax benefits in fiscal 2013 for designated foreign currency and interest rate swap hedges were $1.7 million and $0.3 million, respectively.

ASC Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by ASC Topic 820, Fair Value Measurements and Disclosures, by considering the estimated amount we would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and our creditworthiness for liabilities. In certain instances, we may utilize financial models to measure fair value. Generally, we use inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of March 30, 2013, we have classified our derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC Topic 815, as discussed below, because these observable inputs are available for substantially the full term of our derivative instruments.

The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets as of March 30, 2013 and March 31, 2012 by type of contract and whether it is a qualifying hedge under ASC Topic 815.



(In thousands)	Location in Balance Sheet	Balance as of March 30, 2013		Balance as of March 31, 2012
Derivative Assets:
Designated foreign currency hedge contracts	Other current assets	$	7,030	$	6,186
		$	7,030	$	6,186
Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	954	$	1,185
Designated interest rate swaps	Other current liabilities	671		—
		$	1,625	$	1,185

For the fiscal years ended March 30, 2013 and March 31, 2012, non-designated foreign currency hedge contracts were not significant and are not disclosed separately in the above table.

Other Fair Value Measurements

ASC Topic 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. ASC Topic 820 does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or permit fair value measurements. In accordance with ASC Topic 820, for the fiscal years ended March 30, 2013 and March 31, 2012, we applied the requirements under ASC Topic 820 to our non-financial assets and non-financial liabilities. As we did not have an impairment of any non-financial assets or non-financial liabilities, there was no disclosure required relating to our non-financial assets or non-financial liabilities.

On a recurring basis, we measure certain financial assets and financial liabilities at fair value, including our money market funds, foreign currency hedge contracts, and contingent consideration. ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. We base fair value upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value.

ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:


•	Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.


•	Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.


•	Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

Our money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

Fair Value Measured on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of March 30, 2013 and March 31, 2012:



As of March 30, 2013	Quoted Market Prices for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
	(In thousands)		(In thousands)		(In thousands)		(In thousands)
Assets
Money market funds	$	141,120	$	—	$	—	$	141,120
Foreign currency hedge contracts	—		7,030		—		7,030
	$	141,120	$	7,030	$	—	$	148,150
Liabilities
Foreign currency hedge contracts	$	—	$	954	$	—	$	954
Interest rate swap	—		671		—		671
	$	—	$	1,625	$	—	$	1,625



As of March 31, 2012	Quoted Market Prices for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
	(In thousands)		(In thousands)		(In thousands)		(In thousands)
Assets
Money market funds	$	194,574	$	—	$	—	$	194,574
Forward currency hedge contracts	—		6,186		—		6,186
	$	194,574	$	6,186	$	—	$	200,760
Liabilities
Forward currency hedge contracts	$	—	$	1,185	$	—	$	1,185
	$	—	$	1,185	$	—	$	1,185

For the fiscal years ended March 30, 2013 and March 31, 2012, non-designated foreign currency hedge contracts were not significant and are not disclosed separately in the above tables.

Release of Neoteric Contingent Consideration

Under ASC Topic 805, Business Combinations, we established a liability for payments to former shareholders of Neoteric which were contingent on the performance of the Blood Track business in the first three years post-acquisition, beginning with fiscal 2010. We have reviewed the expected performance versus the performance thresholds for payment. Because the expected performance thresholds will not be achieved, we recorded an adjustment to the fair value of the contingent consideration liability. This appears as contingent consideration income of $1.6 million in the accompanying consolidated statements of income for the fiscal year ended March 31, 2012.

In September 2011, we entered into an agreement to release the Company from the contingent consideration due to the former shareholders of Neoteric. Under the terms of the agreement, the former shareholders of Neoteric received $0.7 million in exchange for releasing the Company from any future claims for contingent consideration. The Company paid the $0.7 million settlement amount during September 2011 and has recorded the associated expense in the selling, general and administrative line item in the accompanying consolidated statements of income.

Other Fair Value Disclosures

The Term Loan is carried at amortized cost and accounts receivable and accounts payable are also reported at their cost which approximates fair value.

INCOME TAXES

12 Months Ended

Mar. 30, 2013

Income Tax Disclosure [Abstract]

INCOME TAXES

Domestic and foreign income before provision for income tax is as follows:



(In thousands)	March 30, 2013		March 31, 2012		April 2, 2011
Domestic	$	17,360	$	40,666	$	58,040
Foreign	32,537		48,832		52,041
Total	$	49,897	$	89,498	$	110,081

The income tax provision contains the following components:



(In thousands)	March 30, 2013			March 31, 2012			April 2, 2011
Current
Federal	$	3,795		$	8,505		$	14,982
State	1,324			2,275			2,111
Foreign	5,389			5,954			7,226
Total current	$	10,508		$	16,734		$	24,319
Deferred
Federal	1,644			7,522			4,931
State	(229		)	(597		)	438
Foreign	(826		)	(1,047		)	413
Total deferred	$	589		$	5,878		$	5,782
Total	$	11,097		$	22,612		$	30,101

Included in the federal income tax provisions for fiscal 2013, 2012 and 2011 are approximately $1.6 million, $2.2 million and $10.8 million, respectively, provided on foreign source income of approximately $4.5 million, $6.2 million and $31.0 million for fiscal years 2013, 2012 and 2011, respectively, for taxes which are payable in the United States.

Tax affected, significant temporary differences comprising the net deferred tax liability are as follows:



(In thousands)	March 30, 2013			March 31, 2012
Depreciation	$	(25,186	)	$	(17,208	)
Amortization	(14,776		)	(19,249		)
Inventory	7,884			4,224
Hedging	(162		)	(589		)
Accruals and reserves	7,208			6,352
Net operating loss carry-forward	1,877			3,354
Stock based compensation	7,834			8,649
Tax credit carry-forward, net	2,243			2,328
Gross deferred taxes	$	(13,078	)	$	(12,139	)
Less valuation allowance	(1,009		)	(1,569		)
Net deferred tax liability	$	(14,087	)	$	(13,708	)

As of March 30, 2013, we have approximately $1.9 million in U.S. acquisition and $0.6 million in foreign related net operating loss carry forwards that it believes are more likely than not that they will be realized. We also have $2.6 million in gross federal and state tax credits available to offset future tax. We have established valuation allowances to reduce the value of tax assets to amounts that it deems to be realizable. The valuation allowance is made up of $0.4 million acquisition related R&D credits and $0.6 million acquisition related net operating losses for fiscal 2013 and $0.4 million and $1.2 million respectively for fiscal 2012. The net operating loss carry forwards are subject to separate limitations and will expire beginning in 2020.

Approximately $200.0 million of our foreign subsidiary undistributed earnings are deemed to be permanently reinvested outside the U.S. Accordingly, we have not provided U.S. income taxes on these earnings. The income tax provision from operations differs from tax provision computed at the 35% U.S. federal statutory income tax rate due to the following:



(In thousands)	March 30, 2013					March 31, 2012					April 2, 2011
Tax at federal statutory rate	$	17,464		35.0	%	$	31,324		35.0	%	$	38,528		35.0	%
Domestic manufacturing deduction	(504		)	(1.0	)%	(700		)	(0.8	)%	(1,120		)	(1.0	)%
Difference between U.S. and foreign tax	(5,584		)	(11.2	)%	(8,539		)	(9.5	)%	(8,610		)	(7.9	)%
State income taxes net of federal benefit	718			1.4	%	1,136			1.3	%	1,741			1.6	%
Repatriation of earnings	—			—	%	—			—	%	(506		)	(0.5	)%
Research credit	(799		)	(1.6	)%	(752		)	(0.9	)%	(209		)	(0.2	)%
Other, net	(198		)	(0.4	)%	143			0.2	%	277			0.3	%
Income tax provision	$	11,097		22.2	%	$	22,612		25.3	%	$	30,101		27.3	%

Unrecognized Tax Benefits

Unrecognized tax benefits represent uncertain tax positions for which reserves have been established. As of March 30, 2013, we had $6.9 million of unrecognized tax benefits, of which $6.7 million will impact the effective tax rate, if recognized. As of March 31, 2012, we had $6.9 million of unrecognized tax benefits, of which $6.6 million will impact the effective tax rate, if recognized.

During the fiscal year ended March 30, 2013 our unrecognized tax benefits were increased by $0.5 million as a result of additional tax benefits arising in the prior year return and current year.

The following table summarizes the activity related to our gross unrecognized tax benefits for the fiscal years ended March 30, 2013, March 31, 2012 and April 2, 2011:



(In thousands)	March 30, 2013			March 31, 2012			April 2, 2011
Beginning Balance	$	6,885		$	4,669		$	4,620
Additions based upon positions related to the current year	1,192			1,124			20
Additions for tax positions of prior years	18			1,216			1,641
Reductions of tax positions	—			(124		)	(1,042		)
Settlements with taxing authorities	(80		)	—			—
Closure of statute of limitations	(1,085		)	—			(570		)
Ending Balance	$	6,930		$	6,885		$	4,669

As of March 30, 2013 we anticipate that the liability for unrecognized tax benefits for uncertain tax positions could change by up to $0.4 million in the next twelve months, as a result of closure of various foreign statutes of limitations.

Our historic practice has been and continues to be to recognize interest and penalties related to Federal, state and foreign income tax matters in income tax expense. Approximately $0.8 million and $1.0 million is accrued for interest at March 30, 2013 and March 31, 2012, respectively and is not included in the amounts above.

We conduct business globally and, as a result, file consolidated and separate Federal, state and foreign income tax returns in multiple jurisdictions. In the normal course of business, we are subject to examination by taxing authorities throughout the world. With a few exceptions overseas, we are no longer subject to U.S. federal, state and local, or foreign income tax examinations for years before 2009.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

NOTES PAYABLE AND LONG-TERM DEBT

12 Months Ended

Mar. 30, 2013

Notes Payable and Long-Term Debt [Abstract]

NOTES PAYABLE AND LONG-TERM DEBT

Notes payable and long-term debt consisted of the following:



(In thousands)	March 30, 2013			March 31, 2012
Term loan, net of financing fees	$	471,016		$	—
Real estate mortgage	2,877			3,771
Bank loan	6,201			—
Less current portion	(23,150		)	(894		)
Long term debt	$	456,944		$	2,877

On August 1, 2012 in connection with the acquisition of the whole blood business, we entered into a credit agreement ("Credit Agreement") with the banks listed below (together, “Lenders”) which provided for a $475.0 million term loan and a $50.0 million revolving loan (the “Revolving Credit Facility,” and together with the Term Loan, (the “Credit Facilities”). The Credit Facilities have a term of five years and mature on August 1, 2017.

Under the terms of this Credit Agreement, the Company may borrow at a spread to an index, including the LIBOR index of 1-month, 3-months, 6-months, etc. From the date of the Credit Agreement, the Company has chosen to borrow against the 1-month USD-LIBOR-BBA rounded up, if necessary, to the nearest 1/16^th of 1%. The terms of the Credit Agreement also allow the Company to borrow in multiple tranches. While the Company currently borrows in a single tranche, in the future, it may choose to borrow in multiple tranches.

At closing, we borrowed the Term Loan and used the proceeds to pay Pall for the acquisition of the assets described in Note 3. The $475.0 million Term Loan bears interest at variable rates determined by Adjusted LIBOR plus a range of 1.125% to 1.500% depending on the achievement of certain leverage ratios. The Revolving Credit Facility bears interest at variable rates similar to the Term Loan. The current margin of the Term Loan is 1.375% over Adjusted LIBOR and our effective interest rate inclusive of prepaid financing costs and other fees was 2.00% as of March 30, 2013.

Revolving loans may be borrowed, repaid and re-borrowed to fund our working capital needs and for other general corporate purposes. No amounts were outstanding under the Revolving Credit Facility at March 30, 2013. The Term Loan or portions thereof may be prepaid at any time, or from time to time without penalty. Once repaid, such amount may not be re-borrowed. The principal amount of the term loan is repayable quarterly over five years and amortizes as follows:



Fiscal Year	Term Loan Amortization Schedule
	(In thousands)
2014	$	17,813
2015	$	47,500
2016	$	71,250
2017	$	190,000
2018	$	148,438

Under the Credit Facilities, we are required to maintain a Consolidated Total Leverage Ratio not to exceed 3.0:1.0 and a Consolidated Interest Coverage Ratio not to be less than 4.0:1.0 during periods when the Credit Facilities are outstanding. In addition, we are required to satisfy these covenants, on a pro forma basis, in connection with any new borrowings (including any letter of credit issuances) on the Revolving Credit Facility as of the time of such borrowings. The Consolidated Interest Coverage Ratio is calculated as the Consolidated EBITDA divided by Consolidated Interest Expense while the Consolidated Total Leverage Ratio is calculated as Consolidated Total Debt divided by Consolidated EBITDA. Consolidated EBITDA includes EBITDA adjusted by non-recurring and unusual transactions specifically as defined in the Credit Facilities.

The Credit Facilities also contain usual and customary non-financial affirmative and negative covenants which include certain restrictions with respect to subsequent indebtedness, liens, loans and investments (including acquisitions), financial reporting obligations, mergers, consolidations, dissolutions or liquidation, asset sales, affiliate transactions, change of our business, capital expenditures, share repurchase and other restricted payments. These covenants are subject to important exceptions and qualifications set forth in the Credit Agreement.

Any failure to comply with the financial and operating covenants of the Credit Facilities would prevent us from being able to borrow additional funds and would constitute a default, which could result in, among other things, the amounts outstanding including all accrued interest and unpaid fees, becoming immediately due and payable. In addition, the Credit Facilities include customary events of default, in certain cases subject to customary cure periods. As of March 30, 2013, we were in compliance with the covenants.

Commitment fee

Pursuant to the Credit Agreement we are required to pay the Lenders, on the last day of each calendar quarter, a commitment fee on the unused portion of the Revolving Credit Facility. The commitment fee is subject to a pricing grid based on our Consolidated Total Leverage Ratio. The commitment fee ranges from 0.175% to 0.300%. The current commitment fee on the undrawn portion of the Revolving Credit Facility is 0.250%.

We may elect to increase the size of the Revolving Credit Facility from $50.0 million to $100.0 million. Alternatively, we may elect to enter into additional term loans up to a $100.0 million combined limit with the Revolving Credit Facility. These elections are subject to the approval of the Administrative Agent and the identification of additional Lenders or current Lenders willing to increase their loan amounts per the terms and conditions contained in the Credit Agreement.

Debt issuance costs and interest

Expenses associated with the issuance of the Term Loan were capitalized and are amortized over the five years using the effective interest method. In connection with the Term Loan, we recorded deferred financing costs of $5.5 million, of which $4.0 million remains as a debt discount. The debt discount is netted against the $475.0 million Term Loan, resulting in a net note payable of $471.0 million. The debt discount will also be amortized over the life of the notes.

Interest expense was $5.9 million and $0.4 million for the fiscal years ended March 30, 2013 and March 31, 2012, respectively. Accrued interest associated with our outstanding debt is included as a component of accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets. As of March 30, 2013, accrued interest totaled $0.1 million.

Parties to the credit facilities

The Lenders party to the Credit Agreement are JP Morgan Chase Bank, N.A., as Administrative Agent, Citibank, N.A. as Syndication Agent, J P Morgan Securities LLC and Citibank, N.A. as Joint Lead Arrangers and Joint Bookrunners, Bank of America, N.A., RBS Citizens, N.A., HSBC Bank USA, N.A., Wells Fargo Bank, N.A., Sumitomo Mitsui Banking Corporation, TD Bank, N.A. and US Bank, N.A. as Co-Documentation Agents, Union Bank, N.A., PNC Bank, National Association and Sovereign Bank, N.A. as Senior Managing Agents and the syndicate lenders that are parties thereto.

Other Credit Facilities

The other debt as of March 30, 2013 includes the real estate mortgage loan of $2.9 million and short term bank borrowings of $6.2 million under operating lines of credit.

In December 2000, we entered into a $10.0 million real estate mortgage agreement (the “Mortgage Agreement”) with an investment firm. The Mortgage Agreement requires principal and interest payments of $0.1 million per month for a period of 180 months, commencing February 1, 2001. The entire balance of the loan may be repaid at any time after February 1, 2006, subject to a prepayment premium, which is calculated based upon the change in the current weekly average yield of Ten (10)-year U.S. Treasury Constant Maturities, the principal balance due and the remaining loan term. The Mortgage Agreement provides for interest to accrue on the unpaid principal balance at a rate of 8.41% per annum. Borrowings under the Mortgage Agreement, with a carrying value of approximately $2.9 million and $3.8 million as of March 30, 2013 and March 31, 2012, respectively, are secured by the land, building and building improvements at our headquarters and manufacturing facility in the U.S.. There are no financial covenants in the terms and conditions of this agreement.

There are short term borrowings of $5.6 million in Japan resulting from fluctuation in their working capital.

Maturity Profile

The maturity profile of long-term debt as of March 30, 2013, after deducting prepaid financing costs is presented below.



Fiscal Year Ending
(In thousands)
2014	$	23,150
2015	47,553
2016	71,416
2017	189,556
2018	148,419
	$	480,094

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Mar. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

We lease facilities and certain equipment under operating leases expiring at various dates through fiscal 2020. Facility leases require us to pay certain insurance expenses, maintenance costs and real estate taxes.

Approximate future basic rental commitments under operating leases as of March 30, 2013 are as follows (in thousands):



Fiscal Year Ending
(In thousands)
2014	$	7,742
2015	6,321
2016	3,445
2017	2,103
2018	1,685
Thereafter	2,689
	$	23,985

Rent expense in fiscal 2013, 2012, and 2011 was $7.0 million, $6.1 million, and $6.6 million, respectively. Some of the Company's operating leases include renewal provisions, escalation clauses and options to purchase the facilities that we lease.

We are presently engaged in various legal actions, and although our ultimate liability cannot be determined at the present time, we believe that any such liability will not materially affect our consolidated financial position or our results of operations.

During the third quarter of fiscal 2013, we issued a field action letter to blood center customers requesting visual inspection of a component of certain whole blood collection sets, due to the potential for a leak to occur at a very low frequency. The component, referred to as a Y connector, was supplied by a contract manufacturer. We have recorded inventory reserves of $7.0 million in cost of goods sold within the consolidated statement of income for the fiscal year ended March 30, 2013 for removal of affected whole blood collection sets from inventory for destruction or rework. We will pursue all available means of financial recovery related to this inventory loss. However, no salvage or recovery value from these efforts was recorded as we cannot currently conclude whether a favorable outcome will result.

During the first quarter of fiscal 2012, we received customer complaints in Europe regarding a quality issue with our High Separation Core Bowl (“HS Core”), a plasma disposable product used primarily to collect plasma for transfusion. Certain of these customers also made subsequent claims regarding financial losses alleged to have been incurred as a result of this matter. Certain of these claims were recoverable under our product liability insurance policy. To date, we have recognized a $10.3 million liability offset by insurance receivables of $8.2 million and an expense of $2.1 million. We collected $4.4 million of insurance receivables during fiscal 2013, which has been classified as an operating cash flow. For the fiscal year ended March 30, 2013, only $0.2 million of the liability remains outstanding. We do not expect to record additional material claims or insurance recoveries related to this matter.

For the past six years, we have pursued patent infringement lawsuits against Fenwal Inc. seeking an injunction and damages from their infringement of a Haemonetics patent, through the sale of the ALYX brand automated red cell collection system, a competitor of our automated red cell collection systems.

Currently, we are pursuing a patent infringement action in Germany against Fenwal (Fresenius), and its European and German subsidiary. On September 20, 2010, we filed a patent infringement action in Germany. In response, Fenwal filed an action to invalidate the Haemonetics patent which is the subject of this infringement action on December 1, 2010.

In April 2008, our subsidiary Haemonetics Italia, Srl. and two of its employees were found guilty by a court in Milan, Italy of charges arising from allegedly improper payments made under a consulting contract with a local physician and in pricing products under a tender from a public hospital. The two employees found guilty in this matter are no longer employed by the Company. On June 14, 2011, the final level appeals court affirmed these verdicts. There are no further appeals available and the convictions are now final. In connection with this conviction, our Italian subsidiary is liable to pay a fine of €147,500 and a proportionate share of the cost of the proceedings. The final amount has not yet been determined.

When this matter first arose, our Board of Directors commissioned independent legal counsel to conduct investigations on its behalf. Based upon its evaluation of counsel's report, the Board concluded that no disciplinary action was warranted in either case. Neither the original ruling nor its final affirmation has impacted the Company's business in Italy to date.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

CAPITAL STOCK

12 Months Ended

Mar. 30, 2013

Capital Stock [Abstract]

CAPITAL STOCK

Stock Plans

The Company has an incentive compensation plan, (the “2005 Incentive Compensation Plan”). The 2005 Incentive Compensation Plan permits the award of non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock, deferred stock/restricted stock units, other stock units and performance shares to the Company’s key employees, officers and directors. The 2005 Incentive Compensation Plan is administered by the Compensation Committee of the Board of Directors (the “Committee”) consisting of three independent members of our Board of Directors. The maximum number of shares available for award under the 2005 Incentive Compensation Plan is 15,024,920. The maximum number of shares that may be issued pursuant to incentive stock options may not exceed 500,000. Any shares that are subject to the award of stock options shall be counted against this limit as one (1) share for every one (1) share issued. Any shares that are subject to awards other than stock options shall be counted against this limit as 3.26 shares for every one (1) share granted. The exercise price for the non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock, deferred stock/restricted stock units, other stock units and performance shares granted under the 2005 Incentive Compensation Plan is determined by the Committee, but in no event shall such exercise price be less than the fair market value of the common stock at the time of the grant. Options, Restricted Stock Awards and Restricted Stock Units become exercisable, or in the case of restricted stock, the resale restrictions are released in a manner determined by the Committee, generally over a four year period for employees and one year from grant for non-employee directors, and all options expire not more than 7 years from the date of the grant. At March 30, 2013, there were 3,876,780 shares subject to options, 354,589 shares of restricted stock outstanding and no shares subject to restricted stock units outstanding under this plan and 6,596,195 shares available for future grant.

The Company had a long-term incentive stock option plan and a non-qualified stock option plan, (the “2000 Long-term Incentive Plan”) which permitted the issuance of a maximum of 7,000,000 shares of our common stock pursuant to incentive and non-qualified stock options granted to key employees, officers and directors. The plan was terminated in connection with the adoption of the 2005 Incentive Compensation Plan. At March 30, 2013, there were 192,978 options outstanding under this plan and no further options will be granted under this plan.

The Company has an Employee Stock Purchase Plan (the “Purchase Plan”) under which a maximum of 1,400,000 shares (subject to adjustment for stock splits and similar changes) of common stock may be purchased by eligible employees. Substantially all of our full-time employees are eligible to participate in the Purchase Plan.

The Purchase Plan provides for two “purchase periods” within each of our fiscal years, the first commencing on November 1 of each year and continuing through April 30 of the next calendar year, and the second commencing on May 1 of each year and continuing through October 31 of such year. Shares are purchased through an accumulation of payroll deductions (of not less than 2% nor more than 15% of compensation, as defined) for the number of whole shares determined by dividing the balance in the employee’s account on the last day of the purchase period by the purchase price per share for the stock determined under the Purchase Plan. The purchase price for shares is the lower of 85% of the fair market value of the common stock at the beginning of the purchase period, or 85% of such value at the end of the purchase period.

Stock-based compensation expense of $11.0 million, $9.3 million, and $10.8 million was recognized under ASC Topic 718, Compensation — Stock Compensation, for the fiscal year ended March 30, 2013, March 31, 2012, and April 2, 2011, respectively. The related income tax benefit recognized was $3.5 million, $2.7 million, and $3.7 million for the fiscal year ended March 30, 2013, March 31, 2012, and April 2, 2011, respectively. We recognize stock-based compensation on a straight line basis.

ASC Topic 718 requires that cash flows relating to the benefits of tax deductions in excess of stock compensation cost recognized be reported as a financing cash flow, rather than as an operating cash flow. This excess tax benefit was $4.1 million, $1.4 million, and $3.1 million for the fiscal year ended March 30, 2013, March 31, 2012, and April 2, 2011, respectively.

A summary of stock option activity for the fiscal year ended March 30, 2013 is as follows:



	Options Outstanding (shares)		Weighted Average Exercise Price per Share		Weighted Average Remaining Life (years)	Aggregate Intrinsic Value ($000’s)
Outstanding at March 31, 2012	4,847,134		$	26.15	3.87	$	42,134
Granted	904,998		38.60
Exercised	(1,402,298	)	22.86
Forfeited	(280,076	)	29.05
Outstanding at March 30, 2013	4,069,758		$	29.85	4.31	$	48,061

Exercisable at March 30, 2013	2,052,602		$	26.42	4.22	$	31,287

Vested or expected to vest at March 30, 2013	3,838,353		$	29.56	3.09	$	46,433

The total intrinsic value of options exercised was $20.9 million, $8.5 million, and $26.5 million during fiscal 2013, 2012, and 2011, respectively.

As of March 30, 2013, there was $12.1 million of total unrecognized compensation cost related to non-vested stock options. This cost is expected to be recognized over a weighted average period of 2.5 years.

The fair value was estimated using the Black-Scholes option-pricing model based on the weighted average of the high and low stock prices at the grant date and the weighted average assumptions specific to the underlying options. Expected volatility assumptions are based on the historical volatility of our common stock. The risk-free interest rate was selected based upon yields of U.S. Treasury issues with a term equal to the expected life of the option being valued. The expected life of the option was estimated with reference to historical exercise patterns, the contractual term of the option and the vesting period. The assumptions utilized for option grants during the periods presented are as follows:



	March 30, 2013		March 31, 2012		April 2, 2011
Volatility	26.4	%	27.5	%	28.2	%
Expected life (years)	4.9		4.9		4.9
Risk-free interest rate	0.8	%	1.1	%	1.8	%
Dividend yield	0.0	%	0.0	%	0.0	%

The weighted average grant date fair value of options to purchase one share granted during 2013, 2012, and 2011 was approximately $9.76, $8.16, and $7.92, respectively.

We have applied, based on an analysis of our historical forfeitures, an annual forfeiture rate of 8% to all unvested stock options as of March 30, 2013 and March 31, 2012, which represents the portion that we expect will be forfeited each year over the vesting period.

The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:



	March 30, 2013		March 31, 2012		April 2, 2011
Volatility	24.9	%	26.3	%	21.1	%
Expected life (months)	6		6		6
Risk-free interest rate	0.2	%	0.1	%	0.2	%
Dividend Yield	0.0	%	0.0	%	0.0	%

The weighted average grant date fair value of the six-month option inherent in the Purchase Plan was approximately $8.50, $7.10, and $5.87 during fiscal 2013, 2012, and 2011, respectively.

Restricted Stock Awards

As of March 30, 2013, there was no unrecognized compensation cost related to non-vested restricted stock awards.

Restricted Stock Units

As of March 30, 2013, there was $8.3 million of total unrecognized compensation cost related to non-vested restricted stock units. This cost is expected to be recognized over a weighted average period of 2.6 years.

A summary of restricted stock units activity for the fiscal year ended March 30, 2013 is as follows:



	Shares		Weighted Average Market Value at Grant Date
Nonvested at March 31, 2012	321,526		$	25.86
Awarded	178,322		32.85
Released	(112,986	)	27.47
Forfeited	(30,443	)	31.23
Nonvested at March 30, 2013	356,419		$	34.06

Accumulated Other Comprehensive Income

A summary of the components of accumulated other comprehensive income is as follows:



(In thousands)	Foreign Currency Translation			Unrealized Gain/(Loss) on Derivatives, Net of Tax			Impact of Defined Benefit Plans, Net of Tax			Accumulated Other Comprehensive Income
Balance, April 3, 2010	$	5,271		$	1,454		$	(820	)	$	5,905
Changes during the year	6,380			(3,299		)	555			3,636
Balance, April 2, 2011	$	11,651		$	(1,845	)	$	(265	)	$	9,541
Changes during the year	(2,813		)	6,370			(3,988		)	(431		)
Balance, March 31, 2012	$	8,838		$	4,525		$	(4,253	)	$	9,110
Changes during the year	(4,705		)	1,848			(820		)	(3,677		)
Balance, March 30, 2013	$	4,133		$	6,373		$	(5,073	)	$	5,433

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

EARNINGS PER SHARE ("EPS")

12 Months Ended

Mar. 30, 2013

Earnings Per Share [Abstract]

EARNINGS PER SHARE (EPS)

EARNINGS PER SHARE (“EPS”)

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations. Basic EPS is computed by dividing net income by weighted average shares outstanding. Diluted EPS includes the effect of potentially dilutive common shares. The common stock weighted average number of shares has been retroactively adjusted for the stock split.



(In thousands, except per share amounts)	March 30, 2013		March 31, 2012		April 2, 2011
Basic EPS
Net income	$	38,800	$	66,886	$	79,980
Weighted average shares	51,349		50,727		50,154
Basic income per share	$	0.76	$	1.32	$	1.59
Diluted EPS
Net income	$	38,800	$	66,886	$	79,980
Basic weighted average shares	51,349		50,727		50,154
Net effect of common stock equivalents	910		863		1,038
Diluted weighted average shares	52,259		51,590		51,192
Diluted income per share	$	0.74	$	1.30	$	1.56

Weighted average shares outstanding, assuming dilution, excludes the impact of 0.5 million, 1.4 million and 2.4 million stock options for fiscal years 2013, 2012 and 2011, respectively, because these securities were anti-dilutive during the noted periods.

PROPERTY, PLANT AND EQUIPMENT

12 Months Ended

Mar. 30, 2013

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT

Property and equipment consisted of the following:



(In thousands)	March 30, 2013			March 31, 2012
Land	$	4,216		$	1,136
Building and building improvements	78,682			58,680
Plant equipment and machinery	205,698			136,057
Office equipment and information technology	103,235			88,185
Haemonetics equipment	240,889			226,476
Total	632,720			510,534
Less: accumulated depreciation and amortization	(375,767		)	(348,877		)
Property, plant and equipment, net	$	256,953		$	161,657

Depreciation expense was $43.4 million, $38.6 million, and $36.8 million for fiscal 2013, 2012, and 2011, respectively.

During fiscal 2013, there was a change in the estimated useful lives of Haemonetics equipment which resulted in a decrease in depreciation expense of $4.5 million, an increase of $3.3 million in net income, and an increase in basic and diluted earnings per share of $0.09.

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

RETIREMENT PLANS

12 Months Ended

Mar. 30, 2013

Compensation and Retirement Disclosure [Abstract]

RETIREMENT PLANS

Defined Contribution Plans

We have a Savings Plus Plan that is a 401(k) plan that allows our U.S. employees to accumulate savings on a pre-tax basis. In addition, matching contributions are made to the Plan based upon pre-established rates. Our matching contributions amounted to approximately $4.9 million in 2013, $4.0 million in 2012, and $3.3 million in 2011. Upon Board approval, additional discretionary contributions can also be made. No discretionary contributions were made for the Savings Plan in fiscal 2013, 2012, or 2011.

Some of our subsidiaries also have defined contribution plans, to which plan both the employee and the employer make contributions. The employer contributions to these plans totaled $2.4 million, $0.8 million, and $1.8 million in fiscal 2013, 2012, and 2011, respectively, of which $1.5 million in fiscal 2011 was contributed for our employees in Switzerland.

Defined Benefit Plans

ASC Topic 715, Compensation — Retirement Benefits, requires an employer to: (a) recognize in its statement of financial position an asset for a plan’s over-funded status or a liability for a plan’s under-funded status; (b) measure a plan’s assets and its obligations that determine its funded status as of the end of the employer’s fiscal year (with limited exceptions); and (c) recognize changes in the funded status of a defined benefit postretirement plan in the year in which the changes occur. Accordingly, the Company is required to report changes in its funded status in comprehensive income on its Statement of Stockholders’ Equity and Comprehensive Income.

Benefits under these plans are generally based on either career average or final average salaries and creditable years of service as defined in the plans. The annual cost for these plans is determined using the projected unit credit actuarial cost method that includes actuarial assumptions and estimates which are subject to change.

Some of the our foreign subsidiaries have defined benefit pension plans covering substantially all full time employees at those subsidiaries. Net periodic benefit costs for the plans in the aggregate include the following components:



(In thousands)	March 30, 2013			March 31, 2012			April 2, 2011
Service cost	$	2,759		$	2,545		$	667
Interest cost on benefit obligation	639			601			283
Expected (return)/loss on plan assets	(413		)	2			(467		)
Actuarial (gain)/loss	196			(385		)	(48		)
Amortization of unrecognized prior service cost	(14		)	(31		)	381
Amortization of unrecognized transition obligation	48			221			30
Totals	$	3,215		$	2,953		$	846

The net periodic benefit costs shown above for fiscal 2013 and fiscal 2012 include the associated costs for the Switzerland defined benefit plan. The net periodic benefit costs for fiscal 2011 shown above have not been updated to reflect the Switzerland plan costs; these costs were approximately $1.5 million. During fiscal 2011, the Switzerland plan was accounted for as a defined contribution plan and Company contributions to the plan were expensed.

The activity under those defined benefit plans are as follows:



(In thousands)	March 30, 2013			March 31, 2012
Change in Benefit Obligation:
Benefit Obligation, beginning of year	$	(27,150	)	$	(22,707	)
Service cost	(2,759		)	(2,545		)
Interest cost	(639		)	(601		)
Benefits paid	3,210			1,952
Actuarial (loss)/gain	(1,364		)	(1,244		)
Employee and plan participants contribution	(2,926		)	(1,728		)
Plan Amendments	—			(193		)
Foreign currency changes	1,502			(84		)
Benefit obligation, end of year	$	(30,126	)	$	(27,150	)
Change in Plan Assets:
Fair value of plan assets, beginning of year	$	18,185		$	15,798
Company contributions	2,381			2,156
Benefits paid	(3,210		)	(1,873		)
Gain/(Loss) on plan assets	397			124
Employee and plan participants contributions	2,926			1,728
Foreign currency changes	(1,102		)	252
Fair value of Plan Assets, end of year	$	19,577		$	18,185
Funded Status	$	(10,549	)	$	(8,965	)
Unrecognized net actuarial loss/(gain)	5,418			4,513
Unrecognized initial obligation	184			141
Unrecognized prior service cost	138			254
Net amount recognized	$	(4,809	)	$	(4,057	)

One of the benefit plans is funded by benefit payments made by the Company. Accordingly that plan has no assets included in the information presented above. The total liability for this plan was $5.4 million and $4.9 million as of March 30, 2013 and March 31, 2012, respectively.

The accumulated benefit obligation for all plans was $22.2 million and $22.5 million for the fiscal year ended March 30, 2013 and March 31, 2012, respectively.

The components of the change recorded in our accumulated other comprehensive income related to our defined benefit plans, net of tax, are as follows (in thousands):



Balance, April 3, 2010	$	(820	)
Obligation at transition	574
Actuarial loss	(50		)
Prior service cost	31
Balance as of April 2, 2011	$	(265	)
Obligation at transition	30
Actuarial loss	(3,701		)
Prior service cost	(317		)
Balance as of March 31, 2012	$	(4,253	)
Obligation at transition	556
Actuarial loss	(1,237		)
Prior service cost	(139		)
Balance as of March 30, 2013	$	(5,073	)

We expect to amortize $0.6 million from accumulated other comprehensive loss during 2014.

The weighted average rates used to determine the net periodic benefit costs were as follows:



	March 30, 2013		March 31, 2012		April 2, 2011
Discount rate	1.97	%	2.40	%	5.30	%
Rate of increased salary levels	1.42	%	1.50	%	2.60	%
Expected long-term rate of return on assets	1.92	%	2.10	%	1.60	%

Assumptions for expected long-term rate of return on plan assets are based upon actual historical returns, future expectations of returns for each asset class and the effect of periodic target asset allocation rebalancing. The results are adjusted for the payment of reasonable expenses of the plan from plan assets. We recognized $0.1 million of deferred taxes in fiscal 2013 .

We have no other material obligation for post-retirement or post-employment benefits.

Our investment policy for pension plans is to balance risk and return through a diversified portfolio to reduce interest rate and market risk. Maturities are managed so that sufficient liquidity exists to meet immediate and future benefit payment requirements.

ASC Topic 820, Fair Value Measurements and Disclosures, provides guidance for reporting and measuring the plan assets of our defined benefit pension plan at fair value as of March 30, 2013. Using the same three-level valuation hierarchy for disclosure of fair value measurements as described in Note 7, all of the assets of the Company’s plan are classified within Level 2 of the fair value hierarchy because the plan assets are primarily insurance contracts.

Expected benefit payments for both plans are estimated using the same assumptions used in determining the company’s benefit obligation at March 30, 2013. Benefit payments will depend on future employment and compensation levels, average years employed and average life spans, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments.

Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows (in thousands):



Expected Benefit Payments
Fiscal Year 2014	$	1,200
Fiscal Year 2015	$	1,327
Fiscal Year 2016	$	1,308
Fiscal Year 2017	$	1,217
Fiscal Year 2018	$	844
Fiscal Year 2019-2023	$	4,714

The Company contributions for fiscal 2014 are expected to be consistent with current year.

SEGMENT INFORMATION

12 Months Ended

Mar. 30, 2013

Segment Reporting [Abstract]

SEGMENT INFORMATION

Segment Definition Criteria

We manage our business on the basis of one operating segment: the design, manufacture, and marketing of blood management solutions. Our chief operating decision-maker uses consolidated results to make operating and strategic decisions. Manufacturing processes, as well as the regulatory environment in which we operate, are largely the same for all product categories.

Enterprise Wide Disclosures About Product and Services

We have four global product families: plasma, blood center, hospital, and software solutions.

Our products include whole blood disposables, equipment devices and the related disposables used with these devices. Disposables include part of plasma, blood center, and hospital product families. Plasma consists of the disposables used to perform apheresis for the separation of whole blood components and subsequent collection of plasma to be used as a raw material for biologically derived pharmaceuticals. Blood center consists of disposables which separate whole blood for the subsequent collection of platelets, plasma, red cells, or a combination of these components for transfusion to patients as well as disposables for manual whole blood collection. Hospital consists of surgical disposables (principally the Cell Saver^® autologous blood recovery system targeted to procedures that involve rapid, high volume blood loss such as cardiovascular surgeries and the cardioPAT^® cardiovascular perioperative autotransfusion system designed to remain with the patient following surgery to recover blood and the patient’s red cells to prepare them for reinfusion), the OrthoPAT^® orthopedic perioperative autotransfusion system designed to operate both during and after surgery to recover and wash the patient’s red cells to prepare them for reinfusion, and diagnostics products (principally the TEG^® Thrombelastograph^® hemostasis analyzer used to help assess a surgical patient’s hemostasis during and after surgery).

Software solutions include information technology platforms that assist blood centers, plasma centers, and hospitals to more effectively manage regulatory compliance and operational efficiency.

Revenues from External Customers:



(In thousands)	March 30, 2013		March 31, 2012		April 2, 2011
Disposable revenues
Plasma disposables	$	268,900	$	258,061	$	227,209
Blood center disposables
Platelet	169,602		167,946		156,251
Red cell	49,733		48,034		46,828
Whole blood	138,436		—		—
	357,771		215,980		203,079
Hospital disposables
Surgical	73,508		66,619		66,503
OrthoPAT	30,230		31,186		35,631
Diagnostics	27,356		23,087		19,414
	131,094		120,892		121,548
Disposables revenue	757,765		594,933		551,836
Software solutions	69,952		70,557		66,876
Equipment & other	64,273		62,354		57,982
Total revenues	$	891,990	$	727,844	$	676,694

Enterprise Wide Disclosures About Product and Services

Year Ended (in thousands)



March 30, 2013	United States		Other North America		Total North America		Japan		Other Asia		Total Europe		Total Consolidated
Sales	$	454,874	$	6,851	$	461,725	$	120,726	$	84,860	$	224,679	$	891,990
Total Assets	$	830,754	$	225,849	$	1,056,603	$	44,189	$	41,037	$	320,088	$	1,461,917
Long-Lived Assets	$	503,606	$	209,439	$	713,045	$	12,977	$	8,076	$	117,717	$	851,815



March 31, 2012	United States		Other North America		Total North America		Japan		Other Asia		Total Europe		Total Consolidated
Sales	$	352,160	$	512	$	352,672	$	124,381	$	67,223	$	183,568	$	727,844
Total Assets	$	634,171	$	15,365	$	649,536	$	50,509	$	27,353	$	183,737	$	911,135
Long-Lived Assets	$	305,370	$	12,796	$	318,166	$	13,128	$	3,961	$	38,009	$	373,264



April 2, 2011	United States		Other North America		Total North America		Japan		Other Asia		Total Europe		Total Consolidated
Sales	$	316,447	$	908	$	317,355	$	110,263	$	61,594	$	187,482	$	676,694
Total Assets	$	582,733	$	15,903	$	598,636	$	47,156	$	18,164	$	169,308	$	833,264
Long-Lived Assets	$	305,305	$	12,715	$	318,020	$	12,391	$	4,181	$	38,092	$	372,684

The Long-Lived Assets reported above include Goodwill, Intangibles and Net Property, Plant and Equipment.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

RESTRUCTURING

12 Months Ended

Mar. 30, 2013

Restructuring and Related Activities [Abstract]

RESTRUCTURING

During fiscal 2012, our restructuring activities primarily consisted of reorganization within our research and development, manufacturing and software operations. Employee-related costs primarily consist of employee severance and benefits. Facility-related costs primarily consist of charges associated with closing facilities, related lease obligations, and other related costs.

For fiscal 2013, we incurred $6.6 million of restructuring charges and a $4.2 million asset write-down. The asset write-down is associated with exiting activities related to technologies originally acquired from Arryx, Inc. Restructuring expenses have been primarily included as a component of selling, general and administrative expense in the accompanying statements of income.

On April 1, 2010, our Board of Directors approved transformation and restructuring plans, which include the integration of Global Med Technologies, Inc. During fiscal 2011, in addition to the costs in the below table and as part of our approved transformation and restructuring plans, we incurred the following expenses:


•	Stock compensation expense of $1.7 million resulting from the acceleration of unvested stock options in accordance to terms of an employment contract for an employee. This expense is included as part of our restructuring charges and reflected in our consolidated statements of income as selling, general and administrative expense for the fiscal year ended April 2, 2011.


•	$2.1 million of integration costs related to the Global Med acquisition.

The following summarizes the restructuring activity for the fiscal year ended March 30, 2013, March 31, 2012, and April 2, 2011, respectively:



(In thousands)	Balance at March 31, 2012		Cost Incurred		Payments			Asset Write down			Restructuring Accrual Balance at March 30, 2013
Employee-related costs	$	1,461	$	6,214	$	(4,586	)	$	—		$	3,089
Facility related costs	533		431		(791		)	—			173
Asset write-down	—		4,247		—			(4,247		)	—
	$	1,994	$	10,892	$	(5,377	)	$	(4,247	)	$	3,262



(In thousands)	Balance at April 2, 2011		Cost Incurred		Payments			Asset Write down		Restructuring Accrual Balance at March 31, 2012
Employee-related costs	$	2,782	$	4,112	$	(5,433	)	$	—	$	1,461
Facility related costs	889		1,746		(2,102		)	—		533
	$	3,671	$	5,858	$	(7,535	)	$	—	$	1,994



(In thousands)	Balance at April 3, 2010		Cost Incurred		Payments			Asset Write down		Restructuring Accrual Balance at April 2, 2011
Employee-related costs	$	9,761	$	3,595	$	(10,574	)	$	—	$	2,782
Facility related costs	—		889		—			—		889
	$	9,761	$	4,484	$	(10,574	)	$	—	$	3,671

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References + Details

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	12 Months Ended
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	Mar. 30, 2013
Capitalization of Software and Development Costs [Abstract]
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS The cost of software that is developed or obtained for internal use is accounted for pursuant to ASC Topic 350, Intangibles — Goodwill and Other. Pursuant to ASC Topic 350, the Company capitalizes costs incurred during the application development stage of software developed for internal use, and expenses costs incurred during the preliminary project and the post-implementation operation stages of development. The Company capitalized $7.5 million and $3.6 million in costs incurred for acquisition of the software license and related software development costs for new internal software that was in the application development stage during the fiscal years ended March 30, 2013 and March 31, 2012, respectively. The capitalized costs are included as a component of property, plant and equipment in the consolidated financial statements. For costs incurred related to the development of software to be sold, leased, or otherwise marketed, the Company applies the provisions of ASC Topic 985-20, Software, which specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers. We capitalized $6.2 million and $6.1 million in software development costs for ongoing initiatives during the fiscal years ended March 30, 2013 and March 31, 2012, respectively. At March 30, 2013 and March 31, 2012, we have a total of $25.7 million and $19.5 million, respectively, of software costs capitalized, of which $20.0 million and $15.4 million, respectively, related to in process software development initiatives. In connection with these development activities, we capitalized interest of $0.3 million and $0.2 million in fiscal 2013 and 2012, respectively. We amortize capitalized costs when the products are released for sale. During the first quarter of fiscal 2013, $1.7 million of capitalized costs related to one project were placed into service, compared to $4.1 million of capitalized costs placed into service during fiscal 2012. Amortization of capitalized software development cost expense was $0.9 million, $0.7 million and $0.2 million for fiscal 2013, 2012 and 2011 respectively. The costs capitalized for each project are included in intangible assets in the consolidated financial statements.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23218-108380

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 86
-Paragraph 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 2
-Paragraph 12, 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Audit and Accounting Guide (AAG)
-Number AAG-FGC
-Paragraph 56, 57
-IssueDate 2006-05-01
-Chapter 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 68
-Paragraph 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

SUMMARY OF QUARTERLY DATA (UNAUDITED)

12 Months Ended

Mar. 30, 2013

Quarterly Financial Data [Abstract]

SUMMARY OF QUARTERLY DATA (UNAUDITED)



(In thousands)	Three months ended
2013	June 30,		September 29,		December 29,		March 30,
Net revenues	$	176,475	$	218,178	$	247,395	$	249,942
Gross profit	$	90,113	$	101,762	$	113,115	$	123,141
Operating income	$	13,079	$	9,901	$	15,747	$	17,710
Net income	$	9,787	$	6,547	$	9,904	$	12,562
Per share data:
Net Income:
Basic	$	0.19	$	0.13	$	0.19	$	0.24
Diluted	$	0.19	$	0.13	$	0.19	$	0.24

	Three months ended
2012	July 2,		October 1,		December 31,		March 31,
Net revenues	$	170,569	$	179,445	$	191,160	$	186,670
Gross profit	$	88,748	$	89,949	$	95,931	$	94,612
Operating income	$	23,908	$	18,566	$	25,324	$	20,960
Net income	$	16,947	$	13,880	$	18,254	$	17,805
Per share data:
Net Income:
Basic	$	0.33	$	0.27	$	0.36	$	0.35
Diluted	$	0.32	$	0.27	$	0.36	$	0.35

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References + Details

SUBSEQUENT EVENTS	12 Months Ended
SUBSEQUENT EVENTS	Mar. 30, 2013
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS Value Creation and Capture On April 29, 2013, we committed to a plan to pursue identified Value Creation and Capture ("VCC") opportunities. These opportunities include investment in product line extensions and next generation products, enhancement of commercial capabilities and a transformation of our manufacturing network. The transformation of our manufacturing network will take place over the next three fiscal years and includes changes to the current manufacturing footprint and supply chain structure (the "Network Plan"). To implement the Network Plan, we will (i) discontinue manufacturing activities at our Braintree, Massachusetts location, (ii) create a technology center of excellence for product development, (iii) expand our current facility in Tijuana, Mexico and (iv) build a new manufacturing facility in Asia closer to our customer base in that region. We estimate we will incur approximately $23.0 million of cash restructuring expenses during fiscal 2014 which will be recorded through cost of goods sold. To complete the Network Plan we estimate that we will spend an additional $8.0 million for cash restructuring expenses in future years. These costs consist principally of employee related costs, product line transfer costs including relocation and validation, as well as redundant overhead and inefficiencies during the transfer period. The management and execution of this effort will require a dedicated team of program managers, engineers, regulatory and quality professionals, the cost of which is included in these estimates. We also expect to incur non-cash costs of approximately $5.0 million consisting of accelerated depreciation and asset write-downs. Activities under the Plan will be initiated in fiscal 2014 and are expected to be substantially completed in the next three years. Additionally, we expect to deploy approximately $36.0 million of cash in fiscal 2014 for capital expenditures to expand our existing Tijuana, Mexico facility and construct a new facility in Asia. We also expect to incur cash costs totaling $29.0 million associated with our other VCC opportunities, completion of the integration of the whole blood business and the recent acquisition of Hemerus. Acquisition of Hemerus On April 30, 2013 we completed the acquisition of certain assets of Hemerus LLC, a Minnesota based company that develops innovative technologies for the collection of whole blood and processing and storage of blood components. Hemerus has received FDA approval for SOLX® whole blood collection system for eight hour storage of whole blood. Hemerus previously received CE Marking (Conformité Européenne) in the European Union to market SOLX as the world's first 56-day red blood cell storage solution. We paid $23.0 million cash in addition to the $1.0 million paid early in fiscal 2013. We will pay an additional $3.0 million upon a further FDA approval of the SOLX solution for 24 hour storage of whole blood prior to processing, and will pay up to $14.0 million on future sales of SOLX-based products.

VALUATION AND QUALIFYING ACCOUNTS

12 Months Ended

Mar. 30, 2013

Valuation and Qualifying Accounts [Abstract]

VALUATION AND QUALIFYING ACCOUNTS

SCHEDULE II

HAEMONETICS CORPORATION

VALUATION AND QUALIFYING ACCOUNTS



(In thousands)	Balance at Beginning of Fiscal Year		Charged to Costs and Expenses			Write-Offs (Net of Recoveries)			Balance at End of Fiscal Year
For Year Ended March 30, 2013
Allowance for Doubtful Accounts	$	1,480	$	446		$	(199	)	$	1,727
For Year Ended March 31, 2012
Allowance for Doubtful Accounts	$	1,799	$	(39	)	$	(280	)	$	1,480
For Year Ended April 2, 2011
Allowance for Doubtful Accounts	$	2,554	$	343		$	(1,098	)	$	1,799

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies)

12 Months Ended

Mar. 30, 2013

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Fiscal Year

Our fiscal year ends on the Saturday closest to the last day of March. Fiscal years 2013, 2012 and 2011each includes 52 weeks with each quarter having 13 weeks.

Principles of Consolidation

Translation of Foreign Currencies

Cash and Cash Equivalents

Allowance for Doubtful Accounts

Property, Plant and Equipment



Asset Classification		Estimated Useful Lives
Building		30 years
Building improvements		5-20 Years
Plant equipment and machinery		3-10 Years
Office equipment and information technology		3-10 Years
Haemonetics equipment		3-7 Years


•	Purchase and consumption of a certain level of disposable product


•	Payment of monthly rental fees


•	An asset utilization performance metric, such as performing a minimum level of procedures per month per device

Goodwill and Other Intangible Assets

Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed

Other Liabilities

Other liabilities represent items payable within the next twelve months.

The items included in the fiscal year end balances were:



(In thousands)	March 30, 2013		March 31, 2012
VAT Liabilities	$	5,121	$	6,875
Forward Contracts	1,786		1,185
Deferred Revenue	23,737		24,132
HS Core Liability (a)	156		3,654
All Other	26,551		21,053
Total	$	57,351	$	56,899


(a)	See Note 10, Commitments and Contingencies, for details of the HS Core quality issue that occurred during the first quarter of 2012.

Research and Development Expenses

All research and development costs are expensed as incurred.

Advertising Costs

All advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statement of income.

Accounting for Shipping and Handling Costs

Income Taxes

Derivative Instruments

Stock-Based Compensation

Expected Volatility — We have principally used our historical volatility as a basis to estimate expected volatility in our valuation of stock options.

Valuation of Acquisitions

Concentration of Credit Risk and Significant Customers

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables)

12 Months Ended

Mar. 30, 2013

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Schedule of Property, Plant and Equipment Estimated Useful Lives



Asset Classification		Estimated Useful Lives
Building		30 years
Building improvements		5-20 Years
Plant equipment and machinery		3-10 Years
Office equipment and information technology		3-10 Years
Haemonetics equipment		3-7 Years

Schedule of Other Accrued Liabilities

The items included in the fiscal year end balances were:



(In thousands)	March 30, 2013		March 31, 2012
VAT Liabilities	$	5,121	$	6,875
Forward Contracts	1,786		1,185
Deferred Revenue	23,737		24,132
HS Core Liability (a)	156		3,654
All Other	26,551		21,053
Total	$	57,351	$	56,899


(a)	See Note 10, Commitments and Contingencies, for details of the HS Core quality issue that occurred during the first quarter of 2012.

ACQUISITIONS (Tables) - Pall Corporation [Member]

12 Months Ended

Mar. 30, 2013

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The preliminary allocation of the purchase price to the estimated fair value of the acquired assets and liabilities is summarized as follows:



Asset class	Amounts Recognized as of March 30, 2013 (Provisional)
(In thousands)
Inventories	$	49,917
Property, plant and equipment	85,984
Intangible assets	188,500
Other assets/liabilities, net	(6,166		)
Goodwill	216,940
Fair value of net assets acquired	$	535,175

Business Acquisition, Pro Forma Information

The following represents the pro forma consolidated statements of income as if the acquisition of the whole blood business had been included in our consolidated results beginning on April 3, 2011.



(In thousands)	March 30, 2013		March 31, 2012
Net sales	$	963,923	$	963,643
Net income	56,540		77,984
Basic earnings per share	$	1.10	$	1.54
Diluted earnings per share	$	1.08	$	1.51



(In thousands)	March 30, 2013			March 31, 2012
Transaction costs (1)	$	3,184		$	3,000
Amortization of inventory fair value adjustment (2)	11,948			(11,948		)
Amortization of acquired intangible assets (3)	(5,236		)	(15,708		)
Interest expense incurred on acquisition financing (4)	(3,173		)	(9,520		)
Selling, general and administrative expenses (5)	(3,513		)	(10,540		)


(1)	Eliminated transactions costs as these non-recurring costs were incurred in fiscal 2013.

(2)


(3)	Added additional amortization of the acquired whole blood intangible assets recognized at fair value in purchase accounting.


(4)	Added additional interest expense for the debt used to finance the acquisition.

(5)

- Definition

Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.

+ References + Details

PRODUCT WARRANTIES (Tables)

12 Months Ended

Mar. 30, 2013

Product Warranties [Abstract]

Schedule of Product Warranty Liability

We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary.



(In thousands)	March 30, 2013			March 31, 2012
Warranty accrual as of the beginning of the period	$	796		$	1,273
Warranty provision	1,180			2,430
Warranty spending	(1,303		)	(2,907		)
Warranty accrual as of the end of the period	$	673		$	796

INVENTORIES (Tables)

12 Months Ended

Mar. 30, 2013

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined on the first-in, first-out method.



(In thousands)	March 30, 2013		March 31, 2012
Raw materials	$	70,716	$	41,219
Work-in-process	7,829		4,640
Finished goods	105,239		71,304
	$	183,784	$	117,163

GOODWILL AND INTANGIBLE ASSETS (Tables)

12 Months Ended

Mar. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The changes in the carrying amount of goodwill for fiscal 2013 and 2012 are as follows:



(In thousands)
Carrying amount as of April 2, 2011	$	115,367
Effect of change in foreign currency exchange rates	(309		)
Carrying amount as of March 31, 2012	$	115,058
Whole blood business (a)	216,940
Effect of change in foreign currency exchange rates	(1,524		)
Carrying amount as of March 30, 2013	$	330,474

Schedule of Amoritized Intangibles



	Gross Carrying Amount		Accumulated Amortization		Net		Weighted Average Useful Life
	(In thousands)		(In thousands)		(In thousands)		(In years)
As of March 30, 2013
Patents	$	8,706	$	6,397	$	2,309	10
Capitalized software	26,841		2,333		24,508		6
Other developed technology	99,486		24,843		74,643		12
Customer contracts and related relationships	196,365		36,552		159,813		12
Trade names	5,383		2,268		3,115		10
Total intangibles	$	336,781	$	72,393	$	264,388	11



	Gross Carrying Amount		Accumulated Amortization		Net		Weighted Average Useful Life
	(In thousands)		(In thousands)		(In thousands)		(In years)
As of March 31, 2012
Patents	$	13,463	$	7,843	$	5,620	11
Capitalized software	20,597		1,394		19,203		6
Other developed technology	42,693		20,120		22,573		11
Customer contracts and related relationships	69,361		23,639		45,722		12
Trade names	5,408		1,977		3,431		10
Total intangibles	$	151,522	$	54,973	$	96,549	11

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References + Details

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Mar. 30, 2013

Derivatives and Fair Value Measurements [Abstract]

Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments



Derivative Instruments	Amount of Gain/(Loss) Recognized in OCI (Effective Portion)			Amount of Gain/(Loss) Reclassified from OCI into Earnings (Effective Portion)			Location in Statement of Operations	Amount of Gain/(Loss) Excluded from Effectiveness Testing (*)			Location in Statement of Operations
(In thousands)
Designated foreign currency hedge contracts, net of tax	$	5,104		$	2,746		Net revenues, COGS, and SG&A	$	(337	)	Other income (expense), net
Non-designated foreign currency hedge contracts	—			—				$	1,214		Other income (expense)
Designated interest rate swaps, net of tax	$	(779	)	$	(269	)	Interest income (expense), net	$	—



(*)		We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.

Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets



(In thousands)	Location in Balance Sheet	Balance as of March 30, 2013		Balance as of March 31, 2012
Derivative Assets:
Designated foreign currency hedge contracts	Other current assets	$	7,030	$	6,186
		$	7,030	$	6,186
Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	954	$	1,185
Designated interest rate swaps	Other current liabilities	671		—
		$	1,625	$	1,185

Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of March 30, 2013 and March 31, 2012:



As of March 30, 2013	Quoted Market Prices for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
	(In thousands)		(In thousands)		(In thousands)		(In thousands)
Assets
Money market funds	$	141,120	$	—	$	—	$	141,120
Foreign currency hedge contracts	—		7,030		—		7,030
	$	141,120	$	7,030	$	—	$	148,150
Liabilities
Foreign currency hedge contracts	$	—	$	954	$	—	$	954
Interest rate swap	—		671		—		671
	$	—	$	1,625	$	—	$	1,625



As of March 31, 2012	Quoted Market Prices for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
	(In thousands)		(In thousands)		(In thousands)		(In thousands)
Assets
Money market funds	$	194,574	$	—	$	—	$	194,574
Forward currency hedge contracts	—		6,186		—		6,186
	$	194,574	$	6,186	$	—	$	200,760
Liabilities
Forward currency hedge contracts	$	—	$	1,185	$	—	$	1,185
	$	—	$	1,185	$	—	$	1,185

- Definition

Tabular disclosure of the location and amount of gains and losses reported in the statement of financial performance, or when applicable, the statement of financial position. For example, (a) gains and losses recognized in the income statement on derivative instruments designated and qualifying as hedging instruments in fair value hedges and related hedged items designated and qualifying in fair value hedges and (b) gains and losses initially recognized in other comprehensive income on derivative instruments designated and qualifying as cash flow hedges.

+ References + Details

INCOME TAXES (Tables)

12 Months Ended

Mar. 30, 2013

Income Tax Disclosure [Abstract]

Schedule Domestic and Foreign Income Before Provision for Income Tax

Domestic and foreign income before provision for income tax is as follows:



(In thousands)	March 30, 2013		March 31, 2012		April 2, 2011
Domestic	$	17,360	$	40,666	$	58,040
Foreign	32,537		48,832		52,041
Total	$	49,897	$	89,498	$	110,081

Schedule of Income Tax Provision Components

The income tax provision contains the following components:



(In thousands)	March 30, 2013			March 31, 2012			April 2, 2011
Current
Federal	$	3,795		$	8,505		$	14,982
State	1,324			2,275			2,111
Foreign	5,389			5,954			7,226
Total current	$	10,508		$	16,734		$	24,319
Deferred
Federal	1,644			7,522			4,931
State	(229		)	(597		)	438
Foreign	(826		)	(1,047		)	413
Total deferred	$	589		$	5,878		$	5,782
Total	$	11,097		$	22,612		$	30,101

Schedule of Net Deferred Tax Asset

Tax affected, significant temporary differences comprising the net deferred tax liability are as follows:



(In thousands)	March 30, 2013			March 31, 2012
Depreciation	$	(25,186	)	$	(17,208	)
Amortization	(14,776		)	(19,249		)
Inventory	7,884			4,224
Hedging	(162		)	(589		)
Accruals and reserves	7,208			6,352
Net operating loss carry-forward	1,877			3,354
Stock based compensation	7,834			8,649
Tax credit carry-forward, net	2,243			2,328
Gross deferred taxes	$	(13,078	)	$	(12,139	)
Less valuation allowance	(1,009		)	(1,569		)
Net deferred tax liability	$	(14,087	)	$	(13,708	)

Schedule of Effective Income Tax Rate Reconciliation

The income tax provision from operations differs from tax provision computed at the 35% U.S. federal statutory income tax rate due to the following:



(In thousands)	March 30, 2013					March 31, 2012					April 2, 2011
Tax at federal statutory rate	$	17,464		35.0	%	$	31,324		35.0	%	$	38,528		35.0	%
Domestic manufacturing deduction	(504		)	(1.0	)%	(700		)	(0.8	)%	(1,120		)	(1.0	)%
Difference between U.S. and foreign tax	(5,584		)	(11.2	)%	(8,539		)	(9.5	)%	(8,610		)	(7.9	)%
State income taxes net of federal benefit	718			1.4	%	1,136			1.3	%	1,741			1.6	%
Repatriation of earnings	—			—	%	—			—	%	(506		)	(0.5	)%
Research credit	(799		)	(1.6	)%	(752		)	(0.9	)%	(209		)	(0.2	)%
Other, net	(198		)	(0.4	)%	143			0.2	%	277			0.3	%
Income tax provision	$	11,097		22.2	%	$	22,612		25.3	%	$	30,101		27.3	%

Summary of Gross Unrecognized Tax Benefits

The following table summarizes the activity related to our gross unrecognized tax benefits for the fiscal years ended March 30, 2013, March 31, 2012 and April 2, 2011:



(In thousands)	March 30, 2013			March 31, 2012			April 2, 2011
Beginning Balance	$	6,885		$	4,669		$	4,620
Additions based upon positions related to the current year	1,192			1,124			20
Additions for tax positions of prior years	18			1,216			1,641
Reductions of tax positions	—			(124		)	(1,042		)
Settlements with taxing authorities	(80		)	—			—
Closure of statute of limitations	(1,085		)	—			(570		)
Ending Balance	$	6,930		$	6,885		$	4,669

- Definition

Tabular disclosure of tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities (i.e., uncertain tax positions) and other types of income tax contingencies, including: (1) the policy on classification of interest and penalties; (2) a tabular reconciliation of the total amounts of unrecognized tax benefits at the beginning and end of the period; the total amount(s) of: (3) unrecognized tax benefits that, if recognized, would affect the effective tax rate, and (4) interest and penalties recognized in each of the income statement and balance sheet; (5) for positions for which it is reasonably possible that the total amounts unrecognized will significantly change within 12 months of the reporting date the: (i) nature of the uncertainty, (ii) nature of the event that could occur that would cause the change, and (iii) an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made; and (6) a description of tax years that remain subject to examination by major tax jurisdictions.

+ References + Details

NOTES PAYABLE AND LONG-TERM DEBT (Tables)

3 Months Ended

12 Months Ended

Mar. 30, 2013

Notes Payable and Long-Term Debt [Abstract]

Schedule of Notes Payable and Long-Term Debt

Notes payable and long-term debt consisted of the following:



(In thousands)	March 30, 2013			March 31, 2012
Term loan, net of financing fees	$	471,016		$	—
Real estate mortgage	2,877			3,771
Bank loan	6,201			—
Less current portion	(23,150		)	(894		)
Long term debt	$	456,944		$	2,877

Schedule of Notes Payable and Long-Term Debt Maturities



Fiscal Year Ending
(In thousands)
2014	$	23,150
2015	47,553
2016	71,416
2017	189,556
2018	148,419
	$	480,094

Schedule of Term Loan Amortization

The Term Loan or portions thereof may be prepaid at any time, or from time to time without penalty. Once repaid, such amount may not be re-borrowed. The principal amount of the term loan is repayable quarterly over five years and amortizes as follows:



Fiscal Year	Term Loan Amortization Schedule
	(In thousands)
2014	$	17,813
2015	$	47,500
2016	$	71,250
2017	$	190,000
2018	$	148,438

COMMITMENTS AND CONTINGENCIES (Tables)

12 Months Ended

Mar. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

Schedule of Approximate Future Basic Rental Commitments under Operating Leases

Approximate future basic rental commitments under operating leases as of March 30, 2013 are as follows (in thousands):



Fiscal Year Ending
(In thousands)
2014	$	7,742
2015	6,321
2016	3,445
2017	2,103
2018	1,685
Thereafter	2,689
	$	23,985

CAPITAL STOCK (Tables)

12 Months Ended

Mar. 30, 2013

Capital Stock [Abstract]

Schedule of Summary of Stock Option Activity

A summary of stock option activity for the fiscal year ended March 30, 2013 is as follows:



	Options Outstanding (shares)		Weighted Average Exercise Price per Share		Weighted Average Remaining Life (years)	Aggregate Intrinsic Value ($000’s)
Outstanding at March 31, 2012	4,847,134		$	26.15	3.87	$	42,134
Granted	904,998		38.60
Exercised	(1,402,298	)	22.86
Forfeited	(280,076	)	29.05
Outstanding at March 30, 2013	4,069,758		$	29.85	4.31	$	48,061

Exercisable at March 30, 2013	2,052,602		$	26.42	4.22	$	31,287

Vested or expected to vest at March 30, 2013	3,838,353		$	29.56	3.09	$	46,433

Schedule of Assumptions Utilized for Estimating Fair Value of Option Grants

The assumptions utilized for option grants during the periods presented are as follows:



	March 30, 2013		March 31, 2012		April 2, 2011
Volatility	26.4	%	27.5	%	28.2	%
Expected life (years)	4.9		4.9		4.9
Risk-free interest rate	0.8	%	1.1	%	1.8	%
Dividend yield	0.0	%	0.0	%	0.0	%

Schedule of Assumptions Used to Estimate Fair Value of Shares Purchased Under ESPP

The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:



	March 30, 2013		March 31, 2012		April 2, 2011
Volatility	24.9	%	26.3	%	21.1	%
Expected life (months)	6		6		6
Risk-free interest rate	0.2	%	0.1	%	0.2	%
Dividend Yield	0.0	%	0.0	%	0.0	%

The weighted average rates used to determine the net periodic benefit costs were as follows:



	March 30, 2013		March 31, 2012		April 2, 2011
Discount rate	1.97	%	2.40	%	5.30	%
Rate of increased salary levels	1.42	%	1.50	%	2.60	%
Expected long-term rate of return on assets	1.92	%	2.10	%	1.60	%

Schedule of Summary of Restricted Stock Units Activity

A summary of restricted stock units activity for the fiscal year ended March 30, 2013 is as follows:



	Shares		Weighted Average Market Value at Grant Date
Nonvested at March 31, 2012	321,526		$	25.86
Awarded	178,322		32.85
Released	(112,986	)	27.47
Forfeited	(30,443	)	31.23
Nonvested at March 30, 2013	356,419		$	34.06

Schedule of Comprehensive Income (Loss)

A summary of the components of accumulated other comprehensive income is as follows:



(In thousands)	Foreign Currency Translation			Unrealized Gain/(Loss) on Derivatives, Net of Tax			Impact of Defined Benefit Plans, Net of Tax			Accumulated Other Comprehensive Income
Balance, April 3, 2010	$	5,271		$	1,454		$	(820	)	$	5,905
Changes during the year	6,380			(3,299		)	555			3,636
Balance, April 2, 2011	$	11,651		$	(1,845	)	$	(265	)	$	9,541
Changes during the year	(2,813		)	6,370			(3,988		)	(431		)
Balance, March 31, 2012	$	8,838		$	4,525		$	(4,253	)	$	9,110
Changes during the year	(4,705		)	1,848			(820		)	(3,677		)
Balance, March 30, 2013	$	4,133		$	6,373		$	(5,073	)	$	5,433

EARNINGS PER SHARE ("EPS") (Tables)

12 Months Ended

Mar. 30, 2013

Earnings Per Share [Abstract]

Schedule of Earnings Per Share Reconciliation



(In thousands, except per share amounts)	March 30, 2013		March 31, 2012		April 2, 2011
Basic EPS
Net income	$	38,800	$	66,886	$	79,980
Weighted average shares	51,349		50,727		50,154
Basic income per share	$	0.76	$	1.32	$	1.59
Diluted EPS
Net income	$	38,800	$	66,886	$	79,980
Basic weighted average shares	51,349		50,727		50,154
Net effect of common stock equivalents	910		863		1,038
Diluted weighted average shares	52,259		51,590		51,192
Diluted income per share	$	0.74	$	1.30	$	1.56

PROPERTY, PLANT AND EQUIPMENT (Tables)

12 Months Ended

Mar. 30, 2013

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment

Property and equipment consisted of the following:



(In thousands)	March 30, 2013			March 31, 2012
Land	$	4,216		$	1,136
Building and building improvements	78,682			58,680
Plant equipment and machinery	205,698			136,057
Office equipment and information technology	103,235			88,185
Haemonetics equipment	240,889			226,476
Total	632,720			510,534
Less: accumulated depreciation and amortization	(375,767		)	(348,877		)
Property, plant and equipment, net	$	256,953		$	161,657

RETIREMENT PLANS (Tables)

12 Months Ended

Mar. 30, 2013

Compensation and Retirement Disclosure [Abstract]

Schedule of Components of Net Periodic Benefit Costs of Defined Benefit Pension Plans



(In thousands)	March 30, 2013			March 31, 2012			April 2, 2011
Service cost	$	2,759		$	2,545		$	667
Interest cost on benefit obligation	639			601			283
Expected (return)/loss on plan assets	(413		)	2			(467		)
Actuarial (gain)/loss	196			(385		)	(48		)
Amortization of unrecognized prior service cost	(14		)	(31		)	381
Amortization of unrecognized transition obligation	48			221			30
Totals	$	3,215		$	2,953		$	846

Schedule of Activity Under Defined Benefit Plans

The activity under those defined benefit plans are as follows:



(In thousands)	March 30, 2013			March 31, 2012
Change in Benefit Obligation:
Benefit Obligation, beginning of year	$	(27,150	)	$	(22,707	)
Service cost	(2,759		)	(2,545		)
Interest cost	(639		)	(601		)
Benefits paid	3,210			1,952
Actuarial (loss)/gain	(1,364		)	(1,244		)
Employee and plan participants contribution	(2,926		)	(1,728		)
Plan Amendments	—			(193		)
Foreign currency changes	1,502			(84		)
Benefit obligation, end of year	$	(30,126	)	$	(27,150	)
Change in Plan Assets:
Fair value of plan assets, beginning of year	$	18,185		$	15,798
Company contributions	2,381			2,156
Benefits paid	(3,210		)	(1,873		)
Gain/(Loss) on plan assets	397			124
Employee and plan participants contributions	2,926			1,728
Foreign currency changes	(1,102		)	252
Fair value of Plan Assets, end of year	$	19,577		$	18,185
Funded Status	$	(10,549	)	$	(8,965	)
Unrecognized net actuarial loss/(gain)	5,418			4,513
Unrecognized initial obligation	184			141
Unrecognized prior service cost	138			254
Net amount recognized	$	(4,809	)	$	(4,057	)

Schedule of Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax

The components of the change recorded in our accumulated other comprehensive income related to our defined benefit plans, net of tax, are as follows (in thousands):



Balance, April 3, 2010	$	(820	)
Obligation at transition	574
Actuarial loss	(50		)
Prior service cost	31
Balance as of April 2, 2011	$	(265	)
Obligation at transition	30
Actuarial loss	(3,701		)
Prior service cost	(317		)
Balance as of March 31, 2012	$	(4,253	)
Obligation at transition	556
Actuarial loss	(1,237		)
Prior service cost	(139		)
Balance as of March 30, 2013	$	(5,073	)

Schedule of Weighted Average Rates Used to Determine Net Periodic Benefit Costs

The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:



	March 30, 2013		March 31, 2012		April 2, 2011
Volatility	24.9	%	26.3	%	21.1	%
Expected life (months)	6		6		6
Risk-free interest rate	0.2	%	0.1	%	0.2	%
Dividend Yield	0.0	%	0.0	%	0.0	%

The weighted average rates used to determine the net periodic benefit costs were as follows:



	March 30, 2013		March 31, 2012		April 2, 2011
Discount rate	1.97	%	2.40	%	5.30	%
Rate of increased salary levels	1.42	%	1.50	%	2.60	%
Expected long-term rate of return on assets	1.92	%	2.10	%	1.60	%

Schedule of Estimated Future Benefit Payments

Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows (in thousands):



Expected Benefit Payments
Fiscal Year 2014	$	1,200
Fiscal Year 2015	$	1,327
Fiscal Year 2016	$	1,308
Fiscal Year 2017	$	1,217
Fiscal Year 2018	$	844
Fiscal Year 2019-2023	$	4,714

SEGMENT INFORMATION (Tables)

12 Months Ended

Mar. 30, 2013

Segment Reporting [Abstract]

Schedule of Revenues from External Customers

Revenues from External Customers:



(In thousands)	March 30, 2013		March 31, 2012		April 2, 2011
Disposable revenues
Plasma disposables	$	268,900	$	258,061	$	227,209
Blood center disposables
Platelet	169,602		167,946		156,251
Red cell	49,733		48,034		46,828
Whole blood	138,436		—		—
	357,771		215,980		203,079
Hospital disposables
Surgical	73,508		66,619		66,503
OrthoPAT	30,230		31,186		35,631
Diagnostics	27,356		23,087		19,414
	131,094		120,892		121,548
Disposables revenue	757,765		594,933		551,836
Software solutions	69,952		70,557		66,876
Equipment & other	64,273		62,354		57,982
Total revenues	$	891,990	$	727,844	$	676,694

Enterprise Wide Disclosures about Product and Services

Enterprise Wide Disclosures About Product and Services

Year Ended (in thousands)



March 30, 2013	United States		Other North America		Total North America		Japan		Other Asia		Total Europe		Total Consolidated
Sales	$	454,874	$	6,851	$	461,725	$	120,726	$	84,860	$	224,679	$	891,990
Total Assets	$	830,754	$	225,849	$	1,056,603	$	44,189	$	41,037	$	320,088	$	1,461,917
Long-Lived Assets	$	503,606	$	209,439	$	713,045	$	12,977	$	8,076	$	117,717	$	851,815



March 31, 2012	United States		Other North America		Total North America		Japan		Other Asia		Total Europe		Total Consolidated
Sales	$	352,160	$	512	$	352,672	$	124,381	$	67,223	$	183,568	$	727,844
Total Assets	$	634,171	$	15,365	$	649,536	$	50,509	$	27,353	$	183,737	$	911,135
Long-Lived Assets	$	305,370	$	12,796	$	318,166	$	13,128	$	3,961	$	38,009	$	373,264



April 2, 2011	United States		Other North America		Total North America		Japan		Other Asia		Total Europe		Total Consolidated
Sales	$	316,447	$	908	$	317,355	$	110,263	$	61,594	$	187,482	$	676,694
Total Assets	$	582,733	$	15,903	$	598,636	$	47,156	$	18,164	$	169,308	$	833,264
Long-Lived Assets	$	305,305	$	12,715	$	318,020	$	12,391	$	4,181	$	38,092	$	372,684

RESTRUCTURING (Tables)

12 Months Ended

Mar. 30, 2013

Restructuring and Related Activities [Abstract]

Schedule of Restructuring Reserve by Type of Cost

The following summarizes the restructuring activity for the fiscal year ended March 30, 2013, March 31, 2012, and April 2, 2011, respectively:



(In thousands)	Balance at March 31, 2012		Cost Incurred		Payments			Asset Write down			Restructuring Accrual Balance at March 30, 2013
Employee-related costs	$	1,461	$	6,214	$	(4,586	)	$	—		$	3,089
Facility related costs	533		431		(791		)	—			173
Asset write-down	—		4,247		—			(4,247		)	—
	$	1,994	$	10,892	$	(5,377	)	$	(4,247	)	$	3,262



(In thousands)	Balance at April 2, 2011		Cost Incurred		Payments			Asset Write down		Restructuring Accrual Balance at March 31, 2012
Employee-related costs	$	2,782	$	4,112	$	(5,433	)	$	—	$	1,461
Facility related costs	889		1,746		(2,102		)	—		533
	$	3,671	$	5,858	$	(7,535	)	$	—	$	1,994



(In thousands)	Balance at April 3, 2010		Cost Incurred		Payments			Asset Write down		Restructuring Accrual Balance at April 2, 2011
Employee-related costs	$	9,761	$	3,595	$	(10,574	)	$	—	$	2,782
Facility related costs	—		889		—			—		889
	$	9,761	$	4,484	$	(10,574	)	$	—	$	3,671

SUMMARY OF QUARTERLY DATA (UNAUDITED) (Tables)

12 Months Ended

Mar. 30, 2013

Quarterly Financial Data [Abstract]

Schedule of Quarterly Data



(In thousands)	Three months ended
2013	June 30,		September 29,		December 29,		March 30,
Net revenues	$	176,475	$	218,178	$	247,395	$	249,942
Gross profit	$	90,113	$	101,762	$	113,115	$	123,141
Operating income	$	13,079	$	9,901	$	15,747	$	17,710
Net income	$	9,787	$	6,547	$	9,904	$	12,562
Per share data:
Net Income:
Basic	$	0.19	$	0.13	$	0.19	$	0.24
Diluted	$	0.19	$	0.13	$	0.19	$	0.24

	Three months ended
2012	July 2,		October 1,		December 31,		March 31,
Net revenues	$	170,569	$	179,445	$	191,160	$	186,670
Gross profit	$	88,748	$	89,949	$	95,931	$	94,612
Operating income	$	23,908	$	18,566	$	25,324	$	20,960
Net income	$	16,947	$	13,880	$	18,254	$	17,805
Per share data:
Net Income:
Basic	$	0.33	$	0.27	$	0.36	$	0.35
Diluted	$	0.32	$	0.27	$	0.36	$	0.35

DESCRIPTION OF BUSINESS (Details)	Oct. 29, 2012 shares
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Stock split, conversion ratio	2

SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details)

12 Months Ended

Mar. 30, 2013

USD ($)

Customers

Mar. 31, 2012

USD ($)

Customers

Apr. 02, 2011

USD ($)

Customers

Summary of Significant Accounting Pronouncements [Line Items]

Term of each fiscal year

1 year

Term of each fiscal quarter

91 days

Cash and cash equivalents maximum maturity period

3 months

Goodwill impairment

$ 0

Other Liabilities

VAT Liabilities

5,121,000

6,875,000

Forward Contracts

1,786,000

1,185,000

Deferred Revenue

23,737,000

24,132,000

All Other

26,551,000

21,053,000

Other liabilities

57,351,000

56,899,000

Advertising expense

4,600,000

4,500,000

2,800,000

Foreign currency losses

800,000

400,000

$ 1,400,000

HS Core Liability

^[1]

$ 156,000

$ 3,654,000

Building

Summary of Significant Accounting Pronouncements [Line Items]

Property, plant and equipment, useful life

30 years

Japanese Red Cross Society [Member] | Sales [Member] | Customer Concentration Risk [Member]

Other Liabilities

Concentration risk, number of customers | Customers

Credit risk, accounts receivable

$ 90,100,000

$ 99,500,000

$ 95,900,000

Japanese Red Cross Society [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]

Other Liabilities

Concentration risk (as a percent)

9.00%

15.30%

13.70%

Italy [Member] | Accounts Receivable [Member] | Deteriorating Credit and Economic Conditions [Member]

Other Liabilities

Credit risk, accounts receivable

$ 23,400,000

$ 21,000,000

Minimum [Member] | Building improvements

Summary of Significant Accounting Pronouncements [Line Items]

Property, plant and equipment, useful life

5 years

Minimum [Member] | Plant equipment and machinery

Summary of Significant Accounting Pronouncements [Line Items]

Property, plant and equipment, useful life

3 years

Minimum [Member] | Office equipment and information technology

Summary of Significant Accounting Pronouncements [Line Items]

Property, plant and equipment, useful life

3 years

Minimum [Member] | Haemonetics equipment

Summary of Significant Accounting Pronouncements [Line Items]

Property, plant and equipment, useful life

3 years

Maximum [Member] | Building improvements

Summary of Significant Accounting Pronouncements [Line Items]

Property, plant and equipment, useful life

20 years

Maximum [Member] | Plant equipment and machinery

Summary of Significant Accounting Pronouncements [Line Items]

Property, plant and equipment, useful life

10 years

Maximum [Member] | Office equipment and information technology

Summary of Significant Accounting Pronouncements [Line Items]

Property, plant and equipment, useful life

10 years

Maximum [Member] | Haemonetics equipment

Summary of Significant Accounting Pronouncements [Line Items]

Property, plant and equipment, useful life

7 years

[1]	See Note 10, Commitments and Contingencies, for details of the HS Core quality issue that occurred during the first quarter of 2012.

ACQUISITIONS (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

12 Months Ended

Mar. 30, 2013

Dec. 29, 2012

Sep. 29, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2011

Oct. 01, 2011

Jul. 02, 2011

Mar. 30, 2013

Mar. 31, 2012

Apr. 02, 2011

Aug. 01, 2012

Dec. 28, 2010

Business Acquisition [Line Items]

Goodwill

$ 330,474

$ 115,058

$ 330,474

$ 115,058

$ 115,367

Amortization expense

22,100

11,400

11,100

Net revenues

249,942

$ 247,395

$ 218,178

$ 176,475

186,670

$ 191,160

$ 179,445

$ 170,569

891,990

727,844

676,694

Net income

12,562

$ 9,904

6,547

$ 9,787

17,805

$ 18,254

$ 13,880

$ 16,947

38,800

66,886

79,980

Cost of goods sold

463,859

358,604

321,485

Pall Corporation [Member]

Business Acquisition [Line Items]

Purchase price

$ 535,200

Consideration sransferred, share amount

500

Inventories

49,917

Property, plant and equipment

85,984

Intangible assets

188,500

Other assets/liabilities, net

(6,166)

Goodwill

216,940

Fair value of net assets acquired

535,175

Net sales

963,923

963,643

Net income

$ 56,540

$ 77,984

Basic earnings per share

$ 1.10

$ 1.54

Diluted earnings per share

$ 1.08

$ 1.51

Transaction costs

^[1]

3,184

3,000

$ 3,184

$ 3,000

Amortization of inventory fair value adjustment

^[2]

11,948

(11,948)

11,948

(11,948)

Amortization of acquired intangible assets

^[3]

(5,236)

(15,708)

(5,236)

(15,708)

Interest expense incurred on acquisition financing

^[4]

(3,173)

(9,520)

(3,173)

(9,520)

Selling, general and administrative expenses

^[5]

(3,513)

$ (10,540)

(3,513)

(10,540)

Amount of transaction prior to acquisition

10,000

Amount owed

1,400

Applied Critical Care Services, Inc. [Member]

Business Acquisition [Line Items]

Purchase price

$ 6,400

Other assets/liabilities, net

800

Goodwill

2,700

Acquired Technology [Member] | Pall Corporation [Member]

Business Acquisition [Line Items]

Intangible assets

61,000

Customer Relationships [Member] | Pall Corporation [Member]

Business Acquisition [Line Items]

Intangible assets

$ 127,500

Customer Relationships [Member] | Applied Critical Care Services, Inc. [Member]

Business Acquisition [Line Items]

Intangible assets

$ 4,500

Acquired Technology and Customer Relationships [Member] | Pall Corporation [Member]

Business Acquisition [Line Items]

Useful life

12 years

Amortization expense

$ 10,500

Replication and Delivery of Certain Manufacturing Assets [Member] | Pall Corporation [Member]

Business Acquisition [Line Items]

Contingent consideration, maximum

15,000

Term Loan [Member] | Pall Corporation [Member]

Business Acquisition [Line Items]

Face amount of debt

$ 475,000

Purchase Price Allocation Adjustments [Member] | Pall Corporation [Member]

Business Acquisition [Line Items]

Inventories

(2,500)

Property, plant and equipment

15,300

Intangible assets

(18,300)

Goodwill

9,900

Assumed liabilities

$ (4,400)

Reportable Segment [Member]

Business Acquisition [Line Items]

Net revenues

757,765

594,933

551,836

Whole Blood [Member] | Reportable Segment [Member]

Business Acquisition [Line Items]

Net revenues

$ 0

Whole Blood [Member] | Reportable Segment [Member] | Pall Corporation [Member]

Business Acquisition [Line Items]

Net revenues

$ 138,436

[1]	Eliminated transactions costs as these non-recurring costs were incurred in fiscal 2013.
[2]	Added additional expense in the period ended March 31, 2012 to reflect the inventory fair value adjustments which would have been amortized had the transaction been consummated on April 3, 2011 as the corresponding inventory would have been completely sold during the first two quarters of 2011. Also, deducted the actual inventory fair value adjustment recorded in the fiscal year ended March 30, 2013 to reflect the pro-forma consumption of inventory in 2011.
[3]	Added additional amortization of the acquired whole blood intangible assets recognized at fair value in purchase accounting.
[4]	Added additional interest expense for the debt used to finance the acquisition.
[5]	Additional investments in infrastructure costs to replicate certain support functions performed by division or corporate organizations of Pall that did not transfer in the acquisition. These costs are primarily related to information technology infrastructure and application costs, and personnel costs required to expand regional and corporate administrative and sales support functions. These costs are not intended to be representative of actual costs incurred by Pall Corporation, and represent Haemonetics' best estimate of future incremental costs on an annualized basis. Actual incremental investments may differ from these estimates.

PRODUCT WARRANTIES (Schedule of Product Warranty Liability) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 30, 2013	Mar. 31, 2012
Product Warranties [Abstract]
General warranty period on parts and labor	1 year	1 year
Product Warranties [Roll Forward]
Warranty accrual as of the beginning of the period	$ 796	$ 1,273
Warranty provision	1,180	2,430
Warranty spending	(1,303)	(2,907)
Warranty accrual as of the end of the period	$ 673	$ 796

INVENTORIES (Schedule of Inventories) (Details) - USD ($) $ in Thousands	Mar. 30, 2013	Mar. 31, 2012
Inventory Disclosure [Abstract]
Raw materials	$ 70,716	$ 41,219
Work-in-process	7,829	4,640
Finished goods	105,239	71,304
Inventories, net	$ 183,784	$ 117,163

GOODWILL AND INTANGIBLE ASSETS Schedule of Goodwill (Details) - USD ($)
$ in Thousands

12 Months Ended

Mar. 30, 2013

Mar. 31, 2012

Goodwill [Roll Forward]

Goodwill, carrying amount

$ 115,058

$ 115,367

Whole blood business

^[1]

216,940

Effect of change in foreign currency exchange rates

(1,524)

(309)

Goodwill, carrying amount

$ 330,474

$ 115,058

[1]	See Note 3, Acquisitions, for a full description of the acquisition of the whole blood assets, which occurred on August 1, 2012.

- Definition

Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph e
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 43
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 72
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph e
-Clause 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph l
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

GOODWILL AND INTANGIBLE ASSETS Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 30, 2013	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Finite-Lived Intangible Assets [Line Items]
Aggregate amortization expense		$ 22,100	$ 11,400	$ 11,100
Future amortization expense, year one	$ 26,200	26,200
Future amortization expense, year two	24,900	24,900
Future amortization expense, year three	24,600	24,600
Future amortization expense, year four	24,500	24,500
Future amortization expense, year five	23,700	23,700
Intangible Assets
Gross Carrying Amount	336,781	336,781	151,522
Accumulated Amortization	72,393	72,393	54,973
Net	264,388	$ 264,388	$ 96,549
Weighted average useful life		11 years	11 years
Cost Incurred		$ 10,892	$ 5,858	$ 4,484
Patents
Intangible Assets
Gross Carrying Amount	8,706	8,706	13,463
Accumulated Amortization	6,397	6,397	7,843
Net	2,309	$ 2,309	$ 5,620
Weighted average useful life		10 years	11 years
Capitalized software
Intangible Assets
Gross Carrying Amount	26,841	$ 26,841	$ 20,597
Accumulated Amortization	2,333	2,333	1,394
Net	24,508	$ 24,508	$ 19,203
Weighted average useful life		6 years	6 years
Other developed technology
Intangible Assets
Gross Carrying Amount	99,486	$ 99,486	$ 42,693
Accumulated Amortization	24,843	24,843	20,120
Net	74,643	$ 74,643	$ 22,573
Weighted average useful life		12 years	11 years
Customer contracts and related relationships
Intangible Assets
Gross Carrying Amount	196,365	$ 196,365	$ 69,361
Accumulated Amortization	36,552	36,552	23,639
Net	159,813	$ 159,813	$ 45,722
Weighted average useful life		12 years	12 years
Trade names
Intangible Assets
Gross Carrying Amount	5,383	$ 5,383	$ 5,408
Accumulated Amortization	2,268	2,268	1,977
Net	3,115	$ 3,115	$ 3,431
Weighted average useful life		10 years	10 years
Arryx Related Assets [Member]
Intangible Assets
Proceeds from sale of intellectual property	900
Minimum [Member]
Intangible Assets
Weighted average useful life		2 years
Maximum [Member]
Intangible Assets
Weighted average useful life		19 years
Asset Write Down [Member] \| Arryx Related Assets [Member]
Intangible Assets
Cost Incurred	$ 4,247

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Sep. 30, 2011	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011	Dec. 29, 2012
Derivative [Line Items]
Deferred tax benefit		$ 589	$ 5,878	$ 5,782
Variable rate basis		LIBOR
Contingent consideration income		$ 0	1,580	1,894
Reversal of interest expense on contingent consideration		$ 0	574	416
Foreign Exchange Contract
Derivative [Line Items]
Percentage of sales generated outside the US		49.00%
Maturity period for foreign currency contracts (in years)		1 year
Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Designated foreign currency hedge contracts outstanding		$ 133,300	162,100
Deferred tax benefit		1,700
Designated as Hedging Instrument \| Interest Rate Swap
Derivative [Line Items]
Deferred tax benefit		300
Designated as Hedging Instrument \| Cash Flow Hedging
Derivative [Line Items]
Gain (loss) on cash flow hedge in earnings		2,500	(3,200)	800
Designated as Hedging Instrument \| Interest Rate Swap
Derivative [Line Items]
Amount of gains (losses) reclassified to earnings within the next twelve months		93
Derivative, Fixed Interest Rate					0.68%
Derivative, Notional Amount					$ 250,000
Not Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Amount of Loss Recognized in OCI (Effective Portion)		0
Non-designated foreign currency hedge contracts outstanding		65,600	45,500
Net Revenues Cost Of Goods Sold And Selling General And Administrative Expense [Member] \| Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Amount of Loss Recognized in OCI (Effective Portion)		5,104	$ 3,140	$ (4,100)
Net Revenues Cost Of Goods Sold And Selling General And Administrative Expense [Member] \| Designated as Hedging Instrument \| Cash Flow Hedging
Derivative [Line Items]
Amount of gains (losses) reclassified to earnings within the next twelve months		5,100
Other income (expense), net \| Designated as Hedging Instrument \| Interest Rate Swap
Derivative [Line Items]
Amount of Loss Recognized in OCI (Effective Portion)		$ (779)
Neoteric [Member]
Derivative [Line Items]
Contingent consideration payment recorded in selling, general and administrative	$ 700

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) - USD ($)
$ in Thousands

12 Months Ended

Mar. 30, 2013

Mar. 31, 2012

Apr. 02, 2011

Designated as Hedging Instrument | Foreign Exchange Contract | Net revenues, COGS, and SG&A

Derivative Instruments, Gain (Loss) [Line Items]

Amount of Loss Recognized in OCI (Effective Portion)

$ 5,104

$ 3,140

$ (4,100)

Amount of Loss Reclassifiedfrom OCI into Earnings (Effective Portion)

2,746

Designated as Hedging Instrument | Foreign Exchange Contract | Interest income (expense), net

Derivative Instruments, Gain (Loss) [Line Items]

Amount Excluded from Effectiveness Testing

^[1]

(337)

Designated as Hedging Instrument | Interest Rate Swap

Derivative Instruments, Gain (Loss) [Line Items]

Amount Excluded from Effectiveness Testing

Designated as Hedging Instrument | Interest Rate Swap | Other income (expense), net

Derivative Instruments, Gain (Loss) [Line Items]

Amount of Loss Recognized in OCI (Effective Portion)

(779)

Amount of Loss Reclassifiedfrom OCI into Earnings (Effective Portion)

(269)

Not Designated as Hedging Instrument | Foreign Exchange Contract

Derivative Instruments, Gain (Loss) [Line Items]

Amount of Loss Recognized in OCI (Effective Portion)

Amount of Loss Reclassifiedfrom OCI into Earnings (Effective Portion)

Not Designated as Hedging Instrument | Foreign Exchange Contract | Interest income (expense), net

Derivative Instruments, Gain (Loss) [Line Items]

Amount Excluded from Effectiveness Testing

^[1]

$ 1,214

[1]	(*) We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets) (Details) - USD ($) $ in Thousands	Mar. 30, 2013	Mar. 31, 2012
Derivative Liabilities:
Derivative Liabilities	$ 1,786	$ 1,185
Designated as Hedging Instrument
Derivative Assets:
Derivative Assets	7,030	6,186
Derivative Liabilities:
Derivative Liabilities	1,625	1,185
Designated as Hedging Instrument \| Foreign Exchange Contract \| Other Current Assets
Derivative Assets:
Derivative Assets	7,030	6,186
Designated as Hedging Instrument \| Foreign Exchange Contract \| Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities	954	1,185
Designated as Hedging Instrument \| Interest Rate Swap \| Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities	$ 671	$ 0

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis) (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Mar. 30, 2013	Mar. 31, 2012
Assets
Money market funds	$ 141,120	$ 194,574
Foreign currency hedge contracts	7,030	6,186
Assets, Fair Value Disclosure, Total	148,150	200,760
Liabilities
Foreign currency hedge contracts	954	1,185
Interest rate swap	671
Liabilities, Fair Value Disclosure, Total	1,625	1,185
Quoted Market Prices for Identical Assets (Level 1) [Member]
Assets
Money market funds	141,120	194,574
Foreign currency hedge contracts	0	0
Assets, Fair Value Disclosure, Total	141,120	194,574
Liabilities
Foreign currency hedge contracts	0	0
Interest rate swap	0
Liabilities, Fair Value Disclosure, Total	0	0
Significant Other Observable Inputs (Level 2) [Member]
Assets
Money market funds	0	0
Foreign currency hedge contracts	7,030	6,186
Assets, Fair Value Disclosure, Total	7,030	6,186
Liabilities
Foreign currency hedge contracts	954	1,185
Interest rate swap	671
Liabilities, Fair Value Disclosure, Total	1,625	1,185
Significant Unobervable Inputs (Level 3) [Member]
Assets
Money market funds	0	0
Foreign currency hedge contracts	0	0
Assets, Fair Value Disclosure, Total	0	0
Liabilities
Foreign currency hedge contracts	0	0
Interest rate swap	0
Liabilities, Fair Value Disclosure, Total	$ 0	$ 0

INCOME TAXES (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
INCOME TAXES (Narrative) (Details) - USD ($) $ in Thousands	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Income Taxes [Line Items]
Foregin source income	$ 32,537	$ 48,832	$ 52,041
Gross federal and state tax credits available to offset future tax	2,600
Acquisition related valuation allowance	1,009	$ 1,569
Gross federal and state tax credits available	$ 200,000
U.S. federal statutory income tax rate	35.00%	35.00%	35.00%
Unrecognized tax benefits	$ 6,930	$ 6,885	$ 4,669	$ 4,620
Unrecognized tax benefits that will impact effective tax rate	6,700	6,600
Unrecognized tax benefitsreduced by expiration of statute of limitations and settlements with taxing authoritites	500
Unrecognized tax positions possible change in the next twelve months	400
Accrued interest and penalties	800	1,000
Internal Revenue Service (IRS) [Member]
Income Taxes [Line Items]
Foreign income tax provision	1,600	2,200	10,800
Foregin source income	4,500	6,200	$ 31,000
United States Acquisitions [Member]
Income Taxes [Line Items]
Acquisition related operating loss carryforwards	1,900
French Acquisition [Member]
Income Taxes [Line Items]
Acquisition related operating loss carryforwards	600
Acquisition Related Research and Development [Member]
Income Taxes [Line Items]
Acquisition related valuation allowance	400	400
Acquisition Related Net Operating Losses [Member]
Income Taxes [Line Items]
Acquisition related valuation allowance	$ 600	$ 1,200

NOTES PAYABLE AND LONG-TERM DEBT (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 31, 2000	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011	Dec. 29, 2012	Aug. 01, 2012	Dec. 02, 2000
Debt Instrument [Line Items]
Variable rate basis		LIBOR
Interest paid		$ 5,910,000	$ 414,000	$ 487,000
Long-term debt		480,094,000
Short-term debt		$ 5,600,000
Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument term		5 years
Debt amortization period		5 years
Basis spread on variable rate		1.375%
Effective interest rate		2.00%
Deferred finance costs		$ 5,500,000
Debt discount		(4,000,000)
Interest payable		100,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Face amount of debt		$ 50,000,000
Debt instrument term		5 years
Credit facility outstanding		$ 0
Consolidated total leverage ratio		3.0
Consolidated interest coverage ratio		4.0
Commitment fee		0.25%
Expanded borrowing capacity including term loans		$ 100,000,000
Credit Agreement [Member]
Debt Instrument [Line Items]
Variable rate basis		1-month USD-LIBOR-BBA
Adjusted libor rounding percentage					0.625%
Term loan, net of financing fees
Debt Instrument [Line Items]
Face amount of debt		$ 471,016,000
Long-term debt			0
Mortgages [Member]
Debt Instrument [Line Items]
Face amount of debt							$ 10,000,000
Debt instrument term							180 months
Long-term debt		2,876,000	3,800,000
Monthly principal and interest payments	$ 100,000
Stated percentage							8.41%
Bank loan
Debt Instrument [Line Items]
Long-term debt		$ 6,201,000	$ 0
Pall Corporation [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Face amount of debt						$ 475,000,000
Minimum [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Basis spread on variable rate		1.125%
Minimum [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Commitment fee		0.175%
Expanded borrowing capacity		$ 50,000,000
Maximum [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Basis spread on variable rate		1.50%
Maximum [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Commitment fee		0.30%
Expanded borrowing capacity		$ 100,000,000

INCOME TAXES (Schedule Domestic and Foreign Income Before Provision for Income Tax) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Income Tax Disclosure [Abstract]
Domestic	$ 17,360	$ 40,666	$ 58,040
Foreign	32,537	48,832	52,041
Income before provision for income taxes	$ 49,897	$ 89,498	$ 110,081

NOTES PAYABLE AND LONG-TERM DEBT (Schedule of Notes Payable and Long-Term Debt) (Details) - USD ($) $ in Thousands	Mar. 30, 2013	Mar. 31, 2012
Debt Instrument [Line Items]
Long-term debt	$ 480,094
Notes payable and current maturities of long-term debt	(23,150)	$ (894)
Long-term debt, net of current maturities	456,944	2,877
Term loan, net of financing fees
Debt Instrument [Line Items]
Face amount of debt	471,016
Long-term debt		0
Real estate mortgage
Debt Instrument [Line Items]
Long-term debt	2,877	3,771
Bank loan
Debt Instrument [Line Items]
Long-term debt	$ 6,201	$ 0

INCOME TAXES (Schedule of Income Tax Provision Components) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Current
Federal	$ 3,795	$ 8,505	$ 14,982
State	1,324	2,275	2,111
Foreign	5,389	5,954	7,226
Total current	10,508	16,734	24,319
Deferred
Federal	1,644	7,522	4,931
State	(229)	(597)	438
Foreign	(826)	(1,047)	413
Total deferred	589	5,878	5,782
Total	$ 11,097	$ 22,612	$ 30,101

NOTES PAYABLE AND LONG-TERM DEBT (Schedule of Term Loan Amortization) (Details) - Term Loan [Member] $ in Thousands	Mar. 30, 2013 USD ($)
Debt Instrument [Line Items]
Amortization of Debt, Year One	$ 17,813
Amortization of Debt, Year Two	47,500
Amortization of Debt, Year Three	71,250
Amortization of Debt, Year Four	190,000
Amortization of Debt, Year Five and Thereafter	$ 148,438

INCOME TAXES (Schedule of Net Deferred Tax Asset) (Details) - USD ($) $ in Thousands	Mar. 30, 2013	Mar. 31, 2012
Income Tax Disclosure [Abstract]
Depreciation	$ (25,186)	$ (17,208)
Amortization	(14,776)	(19,249)
Inventory	7,884	4,224
Hedging	(162)	(589)
Accruals and reserves	7,208	6,352
Net operating loss carry-forward	1,877	3,354
Stock based compensation	7,834	8,649
Tax credit carry-forward, net	2,243	2,328
Gross deferred taxes	(13,078)	(12,139)
Less valuation allowance	(1,009)	(1,569)
Net deferred tax liability	$ (14,087)	$ (13,708)

NOTES PAYABLE AND LONG-TERM DEBT (Schedule of Notes Payable and Long-Term Debt Maturities) (Details) $ in Thousands	Mar. 30, 2013 USD ($)
Notes Payable and Long-Term Debt [Abstract]
2014	$ 23,150
2015	47,553
2016	71,416
2017	189,556
2018	148,419
Long-term debt	$ 480,094

INCOME TAXES (Schedule of Effective Income Tax Rate Reconciliation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Income Tax Disclosure [Abstract]
Tax at federal statutory rate	$ 17,464	$ 31,324	$ 38,528
Tax at federal statutory rate	35.00%	35.00%	35.00%
Domestic manufacturing deduction	$ (504)	$ (700)	$ (1,120)
Domestic manufacturing deduction	(1.00%)	(0.80%)	(1.00%)
Difference between U.S. and foreign tax	$ (5,584)	$ (8,539)	$ (8,610)
Difference between U.S. and foreign tax	(11.20%)	(9.50%)	(7.90%)
State income taxes net of federal benefit	$ 718	$ 1,136	$ 1,741
State income taxes net of federal benefit	1.40%	1.30%	1.60%
Repatriation of earnings	$ 0	$ 0	$ (506)
Repatriation of earnings	0.00%	0.00%	(0.50%)
Research credit	$ (799)	$ (752)	$ (209)
Research credit	(1.60%)	(0.90%)	(0.20%)
Other, net	$ (198)	$ 143	$ 277
Other, net	(0.40%)	0.20%	0.30%
Total	$ 11,097	$ 22,612	$ 30,101
Income tax provision	22.20%	25.30%	27.30%

INCOME TAXES (Summary of Gross Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning Balance	$ 6,885	$ 4,669	$ 4,620
Additions based upon positions related to the current year	1,192	1,124	20
Additions for tax positions of prior years	18	1,216	1,641
Reductions of tax positions	0	(124)	(1,042)
Settlements with taxing authorities	(80)	0	0
Closure of statute of limitations	(1,085)	0	(570)
Ending Balance	$ 6,930	$ 6,885	$ 4,669

COMMITMENTS AND CONTINGENCIES (Schedule of Approximate Future Basic Rental Commitments under Operating Leases) (Details) $ in Thousands	Mar. 30, 2013 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2014	$ 7,742
2015	6,321
2016	3,445
2017	2,103
2018	1,685
Thereafter	2,689
Operating Leases, Future Minimum Payments Due	$ 23,985

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) $ in Thousands	1 Months Ended		12 Months Ended
	Jan. 31, 2009 EUR (€)	Apr. 30, 2008 Employees	Mar. 30, 2013 USD ($)	Mar. 31, 2012 USD ($)	Apr. 02, 2011 USD ($)	Dec. 29, 2012 USD ($)
Loss Contingencies [Line Items]
Rent expense			$ 7,000	$ 6,100	$ 6,600
Inventory reserves recorded in cost of good sold			463,859	$ 358,604	$ 321,485
Damages from Product Defects [Member] \| Certain Whole Blood Collection Sets [Member]
Loss Contingencies [Line Items]
Inventory reserves recorded in cost of good sold			7,000
Damages from Product Defects [Member] \| High Separation Core Bowl [Member]
Loss Contingencies [Line Items]
Accrued loss contingency liability						$ 10,300
Insurance settlements receivable						$ 8,200
Recorded expense, net of insurance recovery			2,100
Remaining liability			$ 200
Fenwal [Member]
Loss Contingencies [Line Items]
Term of patent infringement lawsuits			6 years
Haemonetics Italia, Srl. [Member]
Loss Contingencies [Line Items]
Number of employees found guilty \| Employees		2
Damages awarded \| €	€ 147,500

CAPITAL STOCK (Narrative) (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 30, 2013 USD ($) Members PurchasePeriods $ / shares shares	Mar. 31, 2012 USD ($) $ / shares shares	Apr. 02, 2011 USD ($) $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized \| $	$ 11,000	$ 9,300	$ 10,800
Income tax benefit recognized related to stock-based compensation \| $	3,500	2,700	3,700
Excess tax benefit on exercise of stock options \| $	$ 4,101	$ 1,433	3,124
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)	4,069,758	4,847,134
Total intrinsic value of options exercised \| $	$ 20,900	$ 8,500	$ 26,500
Total unrecognized compensation cost related to non vested awards \| $	$ 12,100
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years)	2 years 6 months
Weighted average grant date fair value of options granted (in dollars per share) \| $ / shares	$ 9.76	$ 8.16	$ 7.92
Annual unvested stock option forfeiture rate (as a percent)	8.00%	8.00%
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost related to non vested awards \| $	$ 0
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity instruments other than options outstanding (in shares)	356,419	321,526
Total unrecognized compensation cost related to non vested awards \| $	$ 8,300
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years)	2 years 7 months 21 days
Long-term Incentive Plan 2000 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)	7,000,000
Long-term Incentive Plan 2000 [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for grant (in shares)	0
Options outstanding (in shares)	192,978
Incentive Compensation Plan 2005 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of members on board of directors (in board members) \| Members	3
Maximum number of shares available for award (in shares)	15,024,920
Maximum number of shares available for grant (in shares)	6,596,195
Number of equity instruments other than options counted against maximum number of award shares for every share granted (in shares)	3.26
Maximum number of years from grant date that options expire (in years)	7 years
Incentive Compensation Plan 2005 [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)	500,000
Number of options counted against maximum number of award shares for every share option issued (in shares)	1
Options outstanding (in shares)	3,876,780
Incentive Compensation Plan 2005 [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period in which awards become exercisable for employees (in years)	4 years
Period after grant that awards become exercisable for non-employee directors (in years)	1 year
Equity instruments other than options outstanding (in shares)	354,589
Incentive Compensation Plan 2005 [Member] \| Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity instruments other than options outstanding (in shares)	0
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)	1,400,000
Number of purchase periods (in purchase periods) \| PurchasePeriods	2
Percentage of purchase price for shares of common stock at fair market value (as a percent)	85.00%
Weighted average grant date fair value of the six-month option inherent in the Purchase Plan (in dollars per share) \| $ / shares	$ 8.50	$ 7.10	$ 5.87
Employee Stock Purchase Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares purchased through payroll deductions (as a percent)	2.00%
Employee Stock Purchase Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares purchased through payroll deductions (as a percent)	15.00%

CAPITAL STOCK (Schedule of Summary of Stock Option Activity) (Details) - Stock Options [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 30, 2013	Mar. 30, 2013	Mar. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options Outstanding, (in shares), Beginning Balance		4,847,134
Options Outstanding, (in shares), Granted		904,998
Options Outstanding, (in shares), Exercised		(1,402,298)
Options Outstanding, (in shares), Forfeited		(280,076)
Options Outstanding, (in shares), Ending Balance	4,069,758	4,069,758	4,847,134
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price (in dollars per share), Beginning Balance		$ 26.15
Weighted Average Exercise Price (in dollars per share), Granted		38.60
Weighted Average Exercise Price (in dollars per share), Exercised		22.86
Weighted Average Exercise Price (in dollars per share), Forfeited		29.05
Weighted Average Exercise Price (in dollars per share), Ending Balance	$ 29.85	$ 29.85	$ 26.15
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	4 years 3 months 22 days		3 years 10 months 13 days
Aggregate Intrinsic Value, Beginning Balance		$ 42,134
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	4 years 3 months 22 days		3 years 10 months 13 days
Aggregate Intrinsic Value, Ending Balance	$ 48,061	$ 48,061	$ 42,134
Options Outstanding, (in shares), Exercisable and End of Period	2,052,602	2,052,602
Weighted Average Exercise Price (in dollars per share), Exercisable at End of Period	$ 26.42	$ 26.42
Weighted Average Remaining Life, Exercisable at End of Period		4 years 2 months 19 days
Aggregate Intrinsic Value, Exercisable at End of Period	$ 31,287	$ 31,287
Options Outstanding, (in shares), Vested and Expected to Vest at End of Period	3,838,353	3,838,353
Weighted Average Exercise Price (in dollars per share), Vested or Expected to Vest at End of Period	$ 29.56	$ 29.56
Weighted Average Remaining Life, Vested or Expected to Vest at End of Period		3 years 1 month 2 days
Aggregate Intrinsic Value, Vested and Expected to Vest at End of Period	$ 46,433	$ 46,433

CAPITAL STOCK (Schedule of Assumptions Utilized for Estimating Fair Value of Option Grants) (Details) - Stock Options [Member]	12 Months Ended
	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	26.40%	27.50%	28.20%
Expected life (years)	4 years 10 months 24 days	4 years 10 months 24 days	4 years 10 months 24 days
Risk-free interest rate	0.80%	1.10%	1.80%
Dividend Yield	0.00%	0.00%	0.00%

CAPITAL STOCK (Schedule of Assumptions Used to Estimate Fair Value of Shares Purchased Under ESPP) (Details) - Employee Stock Purchase Plan [Member]	12 Months Ended
	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	24.90%	26.30%	21.10%
Expected life (months)	6 months	6 months	6 months
Risk-free interest rate	0.20%	0.10%	0.20%
Dividend Yield	0.00%	0.00%	0.00%

CAPITAL STOCK (Schedule of Summary of Restricted Stock Units Activity) (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Mar. 30, 2013 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Shares, Beginning Balance \| shares	321,526
Shares, Awarded \| shares	178,322
Shares, Released \| shares	(112,986)
Shares, Forfeited \| shares	(30,443)
Shares, Ending Balance \| shares	356,419
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Market Value at Grant Date (in dollars per share), Beginning Balance \| $ / shares	$ 25.86
Weighted Average Market Value at Grant Date (in dollars per share), Awarded \| $ / shares	32.85
Weighted Average Market Value at Grant Date (in dollars per share), Released \| $ / shares	27.47
Weighted Average Market Value at Grant Date (in dollars per share), Forfeited \| $ / shares	31.23
Weighted Average Market Value at Grant Date (in dollars per share), Ending Balance \| $ / shares	$ 34.06

CAPITAL STOCK (Schedule of Comprehensive Income (Loss)) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Increase (Decrease) in Comprehensive Income
Foreign Currency Translation, Balance	$ 8,838	$ 11,651	$ 5,271
Foreign Currency Translation, Changes during the year	(4,705)	(2,813)	6,380
Foreign Currency Translation, Balance	4,133	8,838	11,651
Unrealized Gain/(Loss) on Derivatives, Net of Tax, Balance	4,525	(1,845)	1,454
Unrealized Gain/(Loss) on Derivatives, Net of Tax, Changes during the year	1,848	6,370	(3,299)
Unrealized Gain/(Loss) on Derivatives, Net of Tax, Balance	6,373	4,525	(1,845)
Impact of Defined Benefit Plans, Net of Tax, Balance	(4,253)	(265)	(820)
Impact of Defined Benefit Plans, Net of Tax, Changes during the year	(820)	(3,988)	555
Impact of Defined Benefit Plans, Net of Tax, Balance	(5,073)	(4,253)	(265)
Accumulated Other Comprehensive Income, Balance	9,110	9,541	5,905
Accumulated Other Comprehensive Income, Changes during the year	(3,677)	(431)	3,636
Accumulated Other Comprehensive Income, Balance	$ 5,433	$ 9,110	$ 9,541

- Definition

Accumulated change, net of tax, in accumulated gains and losses from derivative instruments designated and qualifying as the effective portion of cash flow hedges. Includes an entity's share of an equity investee's Increase or Decrease in deferred hedging gains or losses.

+ References + Details

- Definition

The total of net gain (loss), prior service cost (credit), and transition assets (obligations), as well as minimum pension liability if still remaining, included in accumulated other comprehensive income associated with a defined benefit pension or other postretirement plan(s) because they have yet to be recognized as components of net periodic benefit cost.

+ References

+ Details

- Definition

Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e681-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669646-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669686-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32022-110900

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 52
-Paragraph 12, 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 45
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 52
-Paragraph 31
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17, 18, 19, 22, 23, 24, 25, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 31
-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 14, 17, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

- Definition

Amount after tax and reclassification adjustments, resulting from the process of expressing in the reporting currency of the reporting entity those amounts that are denominated or measured in a different currency, and from transactions whose terms are denominated in a currency other than the entity's functional currency, which is attributable to the parent entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 29
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

EARNINGS PER SHARE ("EPS") (Schedule of Earnings Per Share Reconciliation) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 30, 2013	Dec. 29, 2012	Sep. 29, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Oct. 01, 2011	Jul. 02, 2011	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Basic EPS
Net income	$ 12,562	$ 9,904	$ 6,547	$ 9,787	$ 17,805	$ 18,254	$ 13,880	$ 16,947	$ 38,800	$ 66,886	$ 79,980
Basic weighted average shares (in shares)									51,349	50,727	50,154
Basic income per share (in dollars per share)	$ 0.24	$ 0.19	$ 0.13	$ 0.19	$ 0.35	$ 0.36	$ 0.27	$ 0.33	$ 0.76	$ 1.32	$ 1.59
Diluted EPS
Net income	$ 12,562	$ 9,904	$ 6,547	$ 9,787	$ 17,805	$ 18,254	$ 13,880	$ 16,947	$ 38,800	$ 66,886	$ 79,980
Basic weighted average shares (in shares)									51,349	50,727	50,154
Net effect of common stock equivalents (in shares)									910	863	1,038
Diluted weighted average shares (in shares)									52,259	51,590	51,192
Diluted income per share (in dollars per share)	$ 0.24	$ 0.19	$ 0.13	$ 0.19	$ 0.35	$ 0.36	$ 0.27	$ 0.32	$ 0.74	$ 1.30	$ 1.56
Stock options excluded from computation of weighted average shares outstanding (in shares)									500	1,400	2,400

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=16381557&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.23)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 18
-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 36, 37, 38
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 20
-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References + Details

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Weighted-Average Number of Common Shares Outstanding
-URI http://asc.fasb.org/extlink&oid=6528421

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 30, 2013	Dec. 29, 2012	Sep. 29, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Oct. 01, 2011	Jul. 02, 2011	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Property, Plant and Equipment [Line Items]
Plant equipment and machinery	$ 205,698				$ 136,057				$ 205,698	$ 136,057
Office equipment and information technology	103,235				88,185				103,235	88,185
Haemonetics equipment	240,889				226,476				240,889	226,476
Total	632,720				510,534				632,720	510,534
Less: accumulated depreciation and amortization	375,767				348,877				375,767	348,877
Property, plant and equipment, net	256,953				161,657				256,953	161,657
Depreciation expense									43,400	38,600	$ 36,800
Net income	$ 12,562	$ 9,904	$ 6,547	$ 9,787	$ 17,805	$ 18,254	$ 13,880	$ 16,947	$ 38,800	$ 66,886	$ 79,980
Basic income per share (in dollars per share)	$ 0.24	$ 0.19	$ 0.13	$ 0.19	$ 0.35	$ 0.36	$ 0.27	$ 0.33	$ 0.76	$ 1.32	$ 1.59
Land
Property, Plant and Equipment [Line Items]
Total	$ 4,216				$ 1,136				$ 4,216	$ 1,136
Building and building improvements
Property, Plant and Equipment [Line Items]
Total	$ 78,682				$ 58,680				78,682	$ 58,680
Service Life [Member]
Property, Plant and Equipment [Line Items]
Depreciation expense									(4,500)
Net income									$ 3,300
Basic income per share (in dollars per share)									$ 0.09

RETIREMENT PLANS (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 30, 2013	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company contributions		$ 2,381	$ 2,156
Net periodic benefit costs		3,215	2,953	$ 846
Benefit obligation	$ 30,126	30,126	27,150	22,707
Accumulated benefit obligation	22,200	22,200	22,500
Amount expected to be amortized from accumulated other comprehensive loss in next fiscal year	600
Deferred taxes recognized	100	100
Savings Plus Plan [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company contributions		4,900	4,000	3,300
Defined Contribution Plans [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company contributions		2,400	800	1,800
Benefit Plan Funded Through Assets of the Company [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Benefit obligation	$ 5,400	$ 5,400	4,900
Switzerland [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Net periodic benefit costs			$ 1,500
Switzerland [Member] \| Defined Contribution Plans [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company contributions				$ 1,500

RETIREMENT PLANS (Schedule of Components of Net Periodic Benefit Costs of Defined Benefit Pension Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Compensation and Retirement Disclosure [Abstract]
Service cost	$ 2,759	$ 2,545	$ 667
Interest cost on benefit obligation	639	601	283
Expected (return)/loss on plan assets	(413)	2	(467)
Actuarial (gain)/loss	196	(385)	(48)
Amortization of unrecognized prior service cost	(14)	(31)	381
Amortization of unrecognized transition obligation	48	221	30
Totals	$ 3,215	$ 2,953	$ 846

- Definition

An amount calculated as a basis for determining the extent of delayed recognition of the effects of changes in the fair value of assets. The expected return on plan assets is determined based on the expected long-term rate of return on plan assets and the market-related value of plan assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 30
-Glossary Expected Return on Plan Assets
-URI http://asc.fasb.org/extlink&oid=6512136

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Glossary Expected Return on Plan Assets
-URI http://asc.fasb.org/extlink&oid=6512171

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)(3)
-URI http://asc.fasb.org/extlink&oid=21915506&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 87
-Paragraph 264
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph h
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 106
-Paragraph 518
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The increase in a defined benefit pension plan's projected benefit obligation or a defined benefit postretirement plan's accumulated postretirement benefit obligation due to the passage of time.

+ References + Details

- Definition

The actuarial present value of benefits attributed by the pension benefit formula to services rendered by employees during the period. The portion of the expected postretirement benefit obligation attributed to employee service during the period. The service cost component is a portion of the benefit obligation and is unaffected by the funded status of the plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Service Cost (Component of Net Periodic Pension Cost)
-URI http://asc.fasb.org/extlink&oid=6525008

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=21915506&loc=d3e1928-114920

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=21915506&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 87
-Paragraph 264
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph a, h
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 106
-Paragraph 518
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

RETIREMENT PLANS (Schedule of Activity Under Defined Benefit Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Change in Benefit Obligation:
Benefit Obligation, beginning of year	$ (27,150)	$ (22,707)
Service cost	(2,759)	(2,545)	$ (667)
Interest cost	(639)	(601)	(283)
Benefits paid	3,210	1,952
Actuarial (loss)/gain	(1,364)	(1,244)
Employee and plan participants contribution	(2,926)	(1,728)
Plan Amendments	0	(193)
Foreign currency changes	1,502	(84)
Benefit obligation, end of year	(30,126)	(27,150)	(22,707)
Change in Plan Assets:
Fair value of plan assets, beginning of year	18,185	15,798
Company contributions	2,381	2,156
Benefits paid	(3,210)	(1,873)
Gain/(Loss) on plan assets	397	124
Employee and plan participants contributions	2,926	1,728
Foreign currency changes	(1,102)	252
Fair value of Plan Assets, end of year	19,577	18,185	$ 15,798
Funded Status	(10,549)	(8,965)
Unrecognized net actuarial loss/(gain)	5,418	4,513
Unrecognized initial obligation	184	141
Unrecognized prior service cost	138	254
Net amount recognized	$ (4,809)	$ (4,057)

RETIREMENT PLANS (Schedule of Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax [Roll Forward]
Impact of Defined Benefit Plans, Net of Tax, Balance	$ (4,253)	$ (265)	$ (820)
Obligation at transition	556	30	574
Actuarial loss	(1,237)	(3,701)	(50)
Prior service cost	(139)	(317)	31
Impact of Defined Benefit Plans, Net of Tax, Balance	$ (5,073)	$ (4,253)	$ (265)

Net of tax amount of the benefit improvement costs resulting from a plan amendment that occurred that has not been recognized in net periodic benefit cost.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=21915506&loc=d3e1928-114920

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 106
-Paragraph 52
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 87
-Paragraph 25
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph i
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 158
-Paragraph 4
-Subparagraph c, d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17, 19, 24
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 158
-Paragraph 7
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

RETIREMENT PLANS (Schedule of Weighted Average Rates Used to Determine Net Periodic Benefit Costs) (Details)	12 Months Ended
	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Compensation and Retirement Disclosure [Abstract]
Discount rate	1.97%	2.40%	5.30%
Rate of increased salary levels	1.42%	1.50%	2.60%
Expected long-term rate of return on assets	1.92%	2.10%	1.60%

RETIREMENT PLANS (Schedule of Estimated Future Benefit Payments) (Details) $ in Thousands	Mar. 30, 2013 USD ($)
Expected Benefit Payments
Fiscal Year 2014	$ 1,200
Fiscal Year 2015	1,327
Fiscal Year 2016	1,308
Fiscal Year 2017	1,217
Fiscal Year 2018	844
Fiscal Year 2019-2023	$ 4,714

SEGMENT INFORMATION (Revenues from External Customers) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 30, 2013	Dec. 29, 2012	Sep. 29, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Oct. 01, 2011	Jul. 02, 2011	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Revenue from External Customer [Line Items]
Total revenues	$ 249,942	$ 247,395	$ 218,178	$ 176,475	$ 186,670	$ 191,160	$ 179,445	$ 170,569	$ 891,990	$ 727,844	$ 676,694
Reportable Segment [Member]
Revenue from External Customer [Line Items]
Total revenues									757,765	594,933	551,836
Reportable Segment [Member] \| Plasma Disposables [Member]
Revenue from External Customer [Line Items]
Total revenues									268,900	258,061	227,209
Reportable Segment [Member] \| Blood Center [Member]
Revenue from External Customer [Line Items]
Total revenues									357,771	215,980	203,079
Reportable Segment [Member] \| Platelet [Member]
Revenue from External Customer [Line Items]
Total revenues									169,602	167,946	156,251
Reportable Segment [Member] \| Red Cell [Member]
Revenue from External Customer [Line Items]
Total revenues									49,733	48,034	46,828
Reportable Segment [Member] \| Whole Blood [Member]
Revenue from External Customer [Line Items]
Total revenues										0	0
Reportable Segment [Member] \| Hospital [Member]
Revenue from External Customer [Line Items]
Total revenues									131,094	120,892	121,548
Reportable Segment [Member] \| Surgical [Member]
Revenue from External Customer [Line Items]
Total revenues									73,508	66,619	66,503
Reportable Segment [Member] \| OrthoPAT [Member]
Revenue from External Customer [Line Items]
Total revenues									30,230	31,186	35,631
Reportable Segment [Member] \| Diagnostics [Member]
Revenue from External Customer [Line Items]
Total revenues									27,356	23,087	19,414
Reportable Segment [Member] \| Software Solutions [Member]
Revenue from External Customer [Line Items]
Total revenues									69,952	70,557	66,876
Reportable Segment [Member] \| Equipment and Other [Member]
Revenue from External Customer [Line Items]
Total revenues									$ 64,273	$ 62,354	$ 57,982

SEGMENT INFORMATION (Enterprise Wide Disclosures about Product and Services) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales	$ 891,990	$ 727,844	$ 676,694
Total Assets	1,461,917	911,135	833,264
Long-Lived Assets	851,815	373,264	372,684
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales	454,874	352,160	316,447
Total Assets	830,754	634,171	582,733
Long-Lived Assets	503,606	305,370	305,305
Other North America [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales	6,851	512	908
Total Assets	225,849	15,365	15,903
Long-Lived Assets	209,439	12,796	12,715
Total North America [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales	461,725	352,672	317,355
Total Assets	1,056,603	649,536	598,636
Long-Lived Assets	713,045	318,166	318,020
Japan
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales	120,726	124,381	110,263
Total Assets	44,189	50,509	47,156
Long-Lived Assets	12,977	13,128	12,391
Other Asia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales	84,860	67,223	61,594
Total Assets	41,037	27,353	18,164
Long-Lived Assets	8,076	3,961	4,181
Total Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales	224,679	183,568	187,482
Total Assets	320,088	183,737	169,308
Long-Lived Assets	$ 117,717	$ 38,009	$ 38,092

RESTRUCTURING (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 30, 2013	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Restructuring Cost and Reserve [Line Items]
Restructuring charges, net impairment charges		$ 6,600
Restructuring charges incurred		10,892	$ 5,858	$ 4,484
Asset write down		4,247	0	$ 0
Asset Write Down [Member]
Restructuring Cost and Reserve [Line Items]
Asset write down		$ 4,247
Stock Compensation Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges incurred			1,700
Global Med Technologies, Inc. [Member] \| Integration Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges incurred			$ 2,100
Arryx Related Assets [Member] \| Asset Write Down [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges incurred	$ 4,247

- Definition

Amount of any reversal and other adjustment made during the period to the amount of a previously accrued liability for a specified type of restructuring cost, excluding adjustments for costs incurred during the period, costs settled during the period, and foreign currency translation adjustments.

+ References + Details

RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 1,994	$ 3,671
Cost Incurred	10,892	5,858	$ 4,484
Payments	(5,377)	(7,535)	(10,574)
Asset Write down	(4,247)	0	0
Ending Balance	3,262	1,994	3,671
Employee-related costs
Restructuring Reserve [Roll Forward]
Beginning Balance	1,461	2,782
Cost Incurred	6,214	4,112	3,595
Payments	(4,586)	(5,433)	(10,574)
Asset Write down	0	0	0
Ending Balance	3,089	1,461	2,782
Facility-related costs
Restructuring Reserve [Roll Forward]
Beginning Balance	533	889
Cost Incurred	431	1,746	889
Payments	(791)	(2,102)	0
Asset Write down	0	0	0
Ending Balance	173	533	$ 889
Asset Write Down [Member]
Restructuring Reserve [Roll Forward]
Beginning Balance	0
Payments	0
Asset Write down	(4,247)
Ending Balance	$ 0	$ 0

- Definition

+ References + Details

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS (Narrative) (Details) $ in Thousands	3 Months Ended		12 Months Ended
	Jun. 30, 2012 USD ($) Projects	Mar. 31, 2012 USD ($)	Mar. 30, 2013 USD ($)	Mar. 31, 2012 USD ($)	Apr. 02, 2011 USD ($)
Schedule of Capitalization [Line Items]
Capitalization of costs incurred for acquisition of the software license and related software development costs			$ 7,500	$ 3,600
Capitalized software development costs for ongoing initiatives			6,200	6,100
Software costs capitalized, net		$ 19,497	25,700	19,497
Total costs capitalized related to in process software development initiatives		15,400	20,000	15,400
Interest costs capitalized			300	200
Amortization of capitalized software development cost expense			$ 900	$ 700	$ 200
In Process Project Placed Into Service [Member]
Schedule of Capitalization [Line Items]
Capitalized software development costs for ongoing initiatives	$ 1,700	$ 4,100
Number of in-process projects \| Projects	1

- Definition

Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preliminary Project Stage
-URI http://asc.fasb.org/extlink&oid=6521637

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Research and Development
-URI http://asc.fasb.org/extlink&oid=6523717

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 98-1
-Paragraph 18-26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 86
-Paragraph 3, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 2
-Paragraph 8, 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 00-2
-Section Exhibit 00-2A
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 86
-Paragraph 11
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

SUMMARY OF QUARTERLY DATA (UNAUDITED) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 30, 2013	Dec. 29, 2012	Sep. 29, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Oct. 01, 2011	Jul. 02, 2011	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Quarterly Financial Data [Abstract]
Net revenues	$ 249,942	$ 247,395	$ 218,178	$ 176,475	$ 186,670	$ 191,160	$ 179,445	$ 170,569	$ 891,990	$ 727,844	$ 676,694
Gross profit	123,141	113,115	101,762	90,113	94,612	95,931	89,949	88,748	428,131	369,240	355,209
Operating income	17,710	15,747	9,901	13,079	20,960	25,324	18,566	23,908	56,437	88,758	110,548
Net income	$ 12,562	$ 9,904	$ 6,547	$ 9,787	$ 17,805	$ 18,254	$ 13,880	$ 16,947	$ 38,800	$ 66,886	$ 79,980
Per share data:
Basic income per share (in dollars per share)	$ 0.24	$ 0.19	$ 0.13	$ 0.19	$ 0.35	$ 0.36	$ 0.27	$ 0.33	$ 0.76	$ 1.32	$ 1.59
Diluted income per share (in dollars per share)	$ 0.24	$ 0.19	$ 0.13	$ 0.19	$ 0.35	$ 0.36	$ 0.27	$ 0.32	$ 0.74	$ 1.30	$ 1.56

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

+ Details

- Definition

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

SUBSEQUENT EVENTS (Details) - Subsequent Event [Member] - USD ($) $ in Millions	Apr. 30, 2013	Apr. 29, 2013
Subsequent Event [Line Items]
Term of the Network Plan		3 years
Estimated Restructuring Expense in Next Fiscal Year		$ 23.0
Estimated Restructuring Expense After One Year		8.0
Estimated Non-Cash Cost, Accelerated Depreciation and Asset Write-Downs		5.0
Estimated Capital Expenditures in Next Fiscal Year		36.0
Estiamted Cash Costs to be Incurred in Next Fiscal Year		$ 29.0
Cash Paid [Member] \| Hemerus Medical, LLC [Member]
Subsequent Event [Line Items]
Purchase price	$ 23.0
Paid Early [Member] \| Hemerus Medical, LLC [Member]
Subsequent Event [Line Items]
Purchase price	1.0
FDA Approval of SOLX [Member] \| Hemerus Medical, LLC [Member]
Subsequent Event [Line Items]
Contingent consideration, maximum	3.0
Future Sales of SOLX [Member] \| Hemerus Medical, LLC [Member]
Subsequent Event [Line Items]
Contingent consideration, maximum	$ 14.0

VALUATION AND QUALIFYING ACCOUNTS (Details) - Allowance for Doubtful Accounts - USD ($) $ in Thousands	12 Months Ended
	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Fiscal Year	$ 1,480	$ 1,799	$ 2,554
Charged to Costs and Expenses	446	(39)	343
Write-Offs (Net of Recoveries)	(199)	(280)	(1,098)
Balance at End of Fiscal Year	$ 1,727	$ 1,480	$ 1,799

Label	Element	Value
Restructuring Reserve	us-gaap_RestructuringReserve	$ 9,761,000
Employee Severance [Member]
Restructuring Reserve	us-gaap_RestructuringReserve	9,761,000
Facility Closing [Member]
Restructuring Reserve	us-gaap_RestructuringReserve	$ 0